<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680430</article-id><article-id pub-id-type="doi">10.3390/vaccines12121439</article-id><article-id pub-id-type="publisher-id">vaccines-12-01439</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6711-3809</contrib-id><name><surname>Meyer</surname><given-names>Thomas</given-names></name><xref rid="c1-vaccines-12-01439" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Stockfleth</surname><given-names>Eggert</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Von Laer</surname><given-names>Dorothee</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01439">Department of Dermatology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany; <email>eggert.stockfleth@klinikum-bochum.de</email></aff><author-notes><corresp id="c1-vaccines-12-01439"><label>*</label>Correspondence: <email>thomas.meyer@klinikum-bochum.de</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1439</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>HPV-associated dermatological diseases include benign lesions like cutaneous warts and external genital warts. In addition, HPV infection is associated with the development of epithelial skin cancers, in particular cutaneous squamous cell carcinoma (cSCC). In contrast to anogenital and oropharyngeal cancers caused by mucosal HPV types of genus alpha papillomavirus, cSCC-associated HPV types belong to the genus beta papillomavirus. Currently available HPV vaccines that target mucosal HPV types associated with anogenital cancer and genital warts are type-specific and provide no cross-protection against beta HPV. When implementing vaccination to beta HPV to prevent skin tumors, it must be considered that acquisition of these HPV types occurs early in childhood and that the risk for cSCC increases with growing age and decreasing immune surveillance. Thus, individuals considered for beta HPV vaccination usually have pre-existing infection and are largely immunocompromised. On the other hand, worldwide increasing incidence rates of epithelial skin cancer reflect an urgent need for skin cancer prevention measures. Based on the pathogenic involvement of beta HPV, vaccination may represent a promising prevention strategy. Indeed, various procedures of prophylactic and therapeutic vaccination have been developed, and some of them have shown efficiency in animal models. Thus far, however, none of these vaccine candidates has been approved for application in humans.</p></abstract><kwd-group><kwd>papillomavirus</kwd><kwd>skin cancer</kwd><kwd>genital warts</kwd><kwd>cutaneous warts</kwd><kwd>oncogene</kwd><kwd>skin microbiome</kwd><kwd>commensal</kwd><kwd>immune surveillance</kwd><kwd>virus-like particle</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01439"><title>1. Introduction</title><p>HPV-associated dermatological diseases include benign lesions like cutaneous warts and external genital warts. In addition, HPV infection is associated with the development of epithelial skin cancers, in particular cutaneous squamous cell carcinoma (cSCC). In general, these skin lesions are associated with specific subsets of HPV types that are different from mucosal HPVs causing cancer of the cervix, vagina, vulva, anus, rectum, penis, and oropharynx [<xref rid="B1-vaccines-12-01439" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-01439" ref-type="bibr">2</xref>]. Due to their oncogenic potential, mucosal cancer-associated HPV types were named high-risk HPVs and include HPV 16 and 18, which are detected most frequently in anogenital and oropharyngeal cancers, as well as another 12 less prevalent HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) [<xref rid="B3-vaccines-12-01439" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01439" ref-type="bibr">4</xref>]. Immunization against high-risk HPVs has been shown to be very effective in preventing HPV infection and subsequent cervical dysplasia and carcinoma [<xref rid="B5-vaccines-12-01439" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01439" ref-type="bibr">6</xref>]. Currently available vaccines are based on virus-like particles (VLPs) that self-assemble from the major capsid protein L1 and induce high levels of neutralizing antibodies that prevent HPV de novo infection [<xref rid="B7-vaccines-12-01439" ref-type="bibr">7</xref>]. Whereas the preventive efficacy of these HPV vaccines is widely accepted, it is controversial whether vaccination with L1-based VLPs may also affect established or active HPV infection. Furthermore, antibodies induced by L1-VLP vaccines are largely type-specific, with limited cross-protection against other HPV types. Thus, when expanding HPV vaccination to skin tumors, it must be considered that other HPV types are involved in skin tumors and acquisition of these HPV types occurs early in childhood by transfer through common household contacts, in contrast to genital HPVs, which are transmitted primarily by sexual contacts [<xref rid="B8-vaccines-12-01439" ref-type="bibr">8</xref>].</p><p>Epithelial skin cancers include basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Together they represent the vast majority (&#x0003e;99%) of nonmelanoma skin cancers (NMSC), whereby BCC are four times more frequent than cSCC (80% vs. 20% of all NMSC). The incidence of these cancers is much higher than that of any other skin cancer. Several studies have shown increasing incidence rates of epithelial skin cancer in different countries, including the United States, United Kingdom, Denmark, and Germany [<xref rid="B9-vaccines-12-01439" ref-type="bibr">9</xref>]. According to the Schleswig-Holstein cancer registry in Germany, age standardized incidence rates of cSCC increased from 39.0 to 68.6 per 100,000 person-years in men and from 19.6 to 36.1 per 100,000 person-years in women between 1999 and 2020. Incidence rates continuously increased for women and men until 2013 and 2015, respectively. The extrapolation of these data for the next 20 years predicts an ongoing increase of age standardized incidence rates, up to 115 per 100,000 person-years in males and 63 per 100,000 person-years in females [<xref rid="B10-vaccines-12-01439" ref-type="bibr">10</xref>]. Thus, an increase of cSCC will be expected, especially in people aged &#x0003e;60 years with men being more frequently affected than women, representing a significant burden for the health care system and reflecting the need for preventive measures [<xref rid="B11-vaccines-12-01439" ref-type="bibr">11</xref>].</p><p>Next to individual factors like age, pigmentation and genetic predisposition (Xeroderma pigmentosum, basal cell nevus syndrome, epidermodysplasia verruciformis) [<xref rid="B12-vaccines-12-01439" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-12-01439" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01439" ref-type="bibr">14</xref>], UV exposure, immune status, and HPV infection represent important environmental risk factors for development of epithelial skin cancers. The most important risk factor for the development of skin cancer is chronic exposure to ultraviolet radiation [<xref rid="B15-vaccines-12-01439" ref-type="bibr">15</xref>]. Although DNA damages caused by UV and high-intensity light may be removed by various DNA repair systems, they may fail over time. Lifetime sun exposure and the number of painful sunburns before the age of 20 years were associated with an increased risk of cSCC, and to a lesser degree with nodal and superficial BCC [<xref rid="B16-vaccines-12-01439" ref-type="bibr">16</xref>].</p><p>The importance of immune surveillance (i.e., immunological functions to control and remove abnormal and malignant cells) for development and progression of cSCC is reflected by the higher risk of cSCC development in organ transplant recipients (OTRs) receiving iatrogenic immunosuppression, which is 65&#x02013;250 times higher than in general population [<xref rid="B17-vaccines-12-01439" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01439" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01439" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01439" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01439" ref-type="bibr">21</xref>]. In addition to UV radiation and immunosuppression, infection with specific cutaneous HPV types may represent another exogenous risk factor for NMSC, described in more detail in the next chapters. Given the association of HPV with development of epithelial skin cancer vaccination against involved HPV types may represent a promising prevention strategy. The number of patients who may benefit from such a vaccine is likely to accumulate in the future, as the frequency of these skin cancers will increase with higher life spans, prolonged exposure to UV-light, and impairment of immune functions.</p><p>In this review we aim to compile vaccination strategies to prevent HPV-associated skin tumors. They differ from the currently available vaccines for mucosal alpha HPVs, as skin-tumor-associated beta HPVs have different biological and oncogenic activities. Therefore, we start with a brief comparison of potential carcinogenic mechanisms of alpha and beta HPVs.</p></sec><sec id="sec2-vaccines-12-01439"><title>2. Human Papillomaviruses (HPV)</title><p>The family of <italic toggle="yes">Papillomaviridae</italic> includes a large number of double-stranded, non-enveloped, small DNA viruses that are widely prevalent in humans and numerous animal species [<xref rid="B22-vaccines-12-01439" ref-type="bibr">22</xref>]. Individual virus types differ with respect to their biological properties, like host specificity, tissue tropism (mucosal or keratinized epithelial cells), and oncogenic potential. In humans, 231 HPV types have been fully sequenced and another 230 partial sequences were identified, probably representing additional HPV types (<uri xlink:href="http://pave.niaid.nih.gov">http://pave.niaid.nih.gov</uri>, <uri xlink:href="http://www.hpvcenter.se">http://www.hpvcenter.se</uri>; searched on 11 December 2024).</p><p>HPV divide into five different genera within the family of <italic toggle="yes">Papillomaviridae</italic>: <italic toggle="yes">alpha-</italic>, <italic toggle="yes">beta-</italic>, <italic toggle="yes">gamma-</italic>, <italic toggle="yes">mu-</italic>, and <italic toggle="yes">nu-papillomavirus</italic> [<xref rid="B23-vaccines-12-01439" ref-type="bibr">23</xref>]. All mucosal HPV types belong to the genus <italic toggle="yes">alpha-papillomavirus</italic>. Some of them were classified as low risk and high-risk HPV types, based on their relative frequency in cervical cancers [<xref rid="B24-vaccines-12-01439" ref-type="bibr">24</xref>]. Most cutaneous HPV types infecting keratinized epithelia belong to the genera <italic toggle="yes">beta-</italic> and <italic toggle="yes">gamma-papillomavirus</italic>. A small number of cutaneous HPVs were classified as <italic toggle="yes">mu-</italic> and <italic toggle="yes">nu-papillomavirus</italic> (<uri xlink:href="http://pave.niaid.nih.gov">http://pave.niaid.nih.gov</uri>). These HPV types are usually associated with benign epithelial lesions. Gamma-, mu-, and nu-HPVs may cause common or plantar warts; beta HPV infection is mostly subclinical or may present as flat warts [<xref rid="B25-vaccines-12-01439" ref-type="bibr">25</xref>]. However, increasing evidence suggests that at least a subset of beta HPV is involved as a co-carcinogen in addition to UV-radiation in the development of cSCC [<xref rid="B26-vaccines-12-01439" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01439" ref-type="bibr">27</xref>].</p><p>Many new HPV types were detected by amplification-based detection methods using consensus primers directed against conserved regions of the HPV genome; however, the spectrum of detected HPV types is limited by the degree of homology of the primers used. In contrast, metagenomic analyses using whole genome sequencing principally allows detection of all HPV sequences. Using these technologies, HPV sequences were detected in condylomata acuminata that tested negative for HPV by traditional PCR methods [<xref rid="B28-vaccines-12-01439" ref-type="bibr">28</xref>]. By comparing sequencing data from 748 samples of 103 healthy human subjects of the NIH Human Microbiome Project (HMP) with HPV sequences available in the Virus Episteme (PaVE) database (<uri xlink:href="http://pave.niaid.nih.gov">http://pave.niaid.nih.gov</uri>) and the International HPV Reference Center (<uri xlink:href="http://www.hpvcenter.se">http://www.hpvcenter.se</uri>), 109 known HPV types and many unclassified types were detected [<xref rid="B29-vaccines-12-01439" ref-type="bibr">29</xref>]. HMP samples were from four different organs and HPV prevalence was highest in skin (61.3%), followed by vagina (41.5%), mouth (30%), and gut (17.3%) with more than one HPV type in most of the samples. These findings indicate a more complex HPV community in healthy humans than previously assumed in studies using HPV detection methods selective for specific HPV types. The presence of multiple HPV types in healthy subjects may indicate a physiological role of HPV. As a possible mechanism, non-oncogenic HPV types in mixed infection may reduce the cancer risk by inhibiting oncogenic viruses through cross-immunity or viral interference [<xref rid="B30-vaccines-12-01439" ref-type="bibr">30</xref>].</p></sec><sec id="sec3-vaccines-12-01439"><title>3. Mechanisms of HPV-Induced Cancers</title><sec id="sec3dot1-vaccines-12-01439"><title>3.1. Alpha HPV</title><p>Upon establishment of the causal relationship of genital HPV infection and cervical cancer in 1983 [<xref rid="B1-vaccines-12-01439" ref-type="bibr">1</xref>], it has been shown that these HPV infections are frequently cleared immunologically in healthy women, but persistent infection with high-risk mucosal HPV types is associated with progression to cervical cancer [<xref rid="B1-vaccines-12-01439" ref-type="bibr">1</xref>]. The HPV genome consists of three regions: the early region containing genes E1, E2, E4, E5, E6, and E7, required for early stages of infection, replication, cell cycle control, and oncogenesis; the late region, containing capsid proteins L1 and L2; and a non-coding long control region involved in control of virus replication and transcription [<xref rid="B31-vaccines-12-01439" ref-type="bibr">31</xref>]. E6 and E7 are the main viral oncoproteins. Their most important oncogenic activity is the inactivation of cellular tumor suppressor proteins p53 and pRB, respectively, resulting in uncontrolled cell proliferation by dysregulation of cell cycle control and apoptosis [<xref rid="B32-vaccines-12-01439" ref-type="bibr">32</xref>]. In most cases of cervical cancer, the HPV genome is integrated into the host genome [<xref rid="B33-vaccines-12-01439" ref-type="bibr">33</xref>], which results in disruption of E2 and activation of E6 and E7 gene expression, as E2 is a negative regulator of oncogene expression [<xref rid="B34-vaccines-12-01439" ref-type="bibr">34</xref>]. In addition, disruption of E2 causes blocking of viral replication, which is depending on interaction of intact E1 and E2 proteins [<xref rid="B35-vaccines-12-01439" ref-type="bibr">35</xref>]. Furthermore, interaction of HPV16 E2 with DNA topoisomerase 2-binding protein 1 (TOPBP1) activates the DNA damage response (DDR) during mitosis to promote TOPBP1 interaction with mitotic chromatin, and thus segregation of the viral genome [<xref rid="B36-vaccines-12-01439" ref-type="bibr">36</xref>]. Next to the inactivation of p53 and pRB, a number of other activities of E6 and E7 proteins were identified that contribute to the oncogenic potential of high-risk alpha HPVs [<xref rid="B1-vaccines-12-01439" ref-type="bibr">1</xref>,<xref rid="B31-vaccines-12-01439" ref-type="bibr">31</xref>,<xref rid="B37-vaccines-12-01439" ref-type="bibr">37</xref>]. These activities result in uncontrolled cell proliferation, inhibition of cell differentiation, apoptosis, and DNA repair, as well as in immortalization, cell invasion, and evasion of immune reactions, which are all features representing so-called hallmarks of cancer.</p><p>While E6 and E7 provide the primary transforming activities of HR-HPV, the E5 protein may augment their functions and contribute to carcinogenesis. The most important oncogenic functions described for E5 include activation of epidermal growth factor receptor (EGF-R) and downstream mitogen-activated protein (MAP) kinase pathways or the PI3K-Akt pathway, as well as suppression of the cyclin-dependent kinase inhibitor p21, which may stimulate cell proliferation and angiogenesis. Furthermore, E5 may contribute to malignant progression by impairing apoptosis [<xref rid="B38-vaccines-12-01439" ref-type="bibr">38</xref>] and by inducing aberrant expression of mesenchymal fibroblast growth factor receptor (FGFR) 2c, epithelial mesenchymal transition, and cell invasion [<xref rid="B39-vaccines-12-01439" ref-type="bibr">39</xref>]. As the E5 gene is frequently deleted during integration of the HPV genome, the role in carcinogenesis seems to be limited to early stages of malignant progression [<xref rid="B1-vaccines-12-01439" ref-type="bibr">1</xref>].</p></sec><sec id="sec3dot2-vaccines-12-01439"><title>3.2. Beta HPV</title><p>High-risk mucosal HPVs may be considered pathogenic tumor viruses that cause symptomatic infections. In contrast, beta HPVs usually do not cause symptoms and are ubiquitously present in humans, thus rather representing commensal than pathogenic viruses. In fact, the ubiquitous prevalence of beta HPVs in the general healthy population [<xref rid="B40-vaccines-12-01439" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-01439" ref-type="bibr">41</xref>] raise doubts about a causal involvement in cSCC development. Furthermore, beta HPVs lack the E5 gene and do not integrate into the host cellular genome [<xref rid="B41-vaccines-12-01439" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-12-01439" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-12-01439" ref-type="bibr">43</xref>]. Thus, E5 seems to have given a carcinogenetic boost to alpha HPVs compared to beta HPVs. Beta HPVs were detected in both normal skin and skin tumors and are more prevalent in precancerous lesions than in skin cancers (keratinocyte cancers, KC). The viral load and viral gene expression is also higher in precancerous lesions than in KC [<xref rid="B44-vaccines-12-01439" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01439" ref-type="bibr">45</xref>].</p><p>However, OTRs, who require immunosuppressive therapy, have an increased risk for KC, in particular cSCC, and also have an increased risk for beta HPV infection [<xref rid="B17-vaccines-12-01439" ref-type="bibr">17</xref>]. Whereas beta HPVs were detected in up to 90% of healthy skin of both immunocompetent and immunocompromised patients, beta HPV DNA is detected in 80% of cSCC of immunosuppressed patients, compared to 40% of cSCC of immunocompetent patients [<xref rid="B46-vaccines-12-01439" ref-type="bibr">46</xref>]. Furthermore, in OTRs, beta HPV detection rates in hair follicles and antibodies against beta HPV correlate with cSCC development [<xref rid="B26-vaccines-12-01439" ref-type="bibr">26</xref>,<xref rid="B47-vaccines-12-01439" ref-type="bibr">47</xref>], indicating that immunosuppression leads to higher beta HPV loads and increased oncogenic activity, which in turn increases the risk of cSCC development [<xref rid="B48-vaccines-12-01439" ref-type="bibr">48</xref>].</p><p>Further evidence for involvement of beta HPV in skin carcinogenesis is provided by several in vivo studies using <italic toggle="yes">Mastomys natalensis papillomavirus</italic> (MnPV) and transgenic mice models. When <italic toggle="yes">Mastomys coucha</italic> animals were infected with MnPV, most of them developed cSCC when exposed to UV radiation, whereas few animals not infected with MnPV but exposed to the same UV dose, as well as non-UV-exposed but MnPV-infected animals, develop cSCC [<xref rid="B49-vaccines-12-01439" ref-type="bibr">49</xref>]. In other studies with transgenic mice containing the HPV8 early region under control of the keratin 14 promoter to limit expression to the basal layer, spontaneous development of cSCC and other cutaneous lesions was shown [<xref rid="B50-vaccines-12-01439" ref-type="bibr">50</xref>]. Integration of E6 and E7 of HPV38 and exposure to chronic UV radiation results in development of actinic keratosis (AK)-like lesions and cSCC, in contrast to wild-type mice that do not develop skin tumors when exposed to the same UV dose [<xref rid="B51-vaccines-12-01439" ref-type="bibr">51</xref>]. Knocking down HPV8 E6 expression with gene specific siRNA resulted in delayed or absent development of papillomas [<xref rid="B52-vaccines-12-01439" ref-type="bibr">52</xref>], indicating HPV8 gene expression seems to be required for tumor development. In addition, silencing of E6 and E7 expression in transgenic mice with already existing cSCC did not affect the tumor phenotype, indicating a role of HPV in the early steps of skin carcinogenesis [<xref rid="B53-vaccines-12-01439" ref-type="bibr">53</xref>].</p><p>In contrast to alpha HPVs, E6 proteins of beta HPVs do not bind to the ubiquitin ligase E6AP. Instead, beta HPV E6 proteins interact with the Mastermind-like transcriptional coactivator 1 (MAML1) to inhibit signaling of NOTCH, a tumor suppressor in squamous epithelial cells [<xref rid="B54-vaccines-12-01439" ref-type="bibr">54</xref>]. In addition, beta HPV E6 induces degradation of acyltransferase p300, resulting in reduced expression of breast cancer (BRCA) 1 and BRCA 2, and thus impairing double-strand DNA repair (DSR) mechanisms [<xref rid="B55-vaccines-12-01439" ref-type="bibr">55</xref>].</p><p>On the other hand, E7 of both alpha and beta HPV bind to pRB, although binding of at least some beta HPV types is weaker than for alpha HPVs [<xref rid="B56-vaccines-12-01439" ref-type="bibr">56</xref>]. A number of other mechanisms were described for beta HPVs that interfere with cellular functions, like cell cycle control, apoptosis, DNA repair, keratinocyte differentiation, and immune functions, and thus may be considered tumor-promoting activities [<xref rid="B26-vaccines-12-01439" ref-type="bibr">26</xref>,<xref rid="B37-vaccines-12-01439" ref-type="bibr">37</xref>,<xref rid="B57-vaccines-12-01439" ref-type="bibr">57</xref>]. Many of these mechanisms vary among beta HPVs with respect to potency, or have only been shown in subsets of beta HPVs [<xref rid="B58-vaccines-12-01439" ref-type="bibr">58</xref>].</p><p>Of importance, however, inhibition of Notch signaling and p300 results in cell proliferation despite impaired double-strand DNA repair (DSR) and inhibition of apoptosis that may allow accumulation of genomic mutations required to progress to cancer. This points towards a role of beta HPVs in early stages of cSCC development, with viral activities involved in the initiation of cell transformation that are no longer required for tumor maintenance, consistent with a &#x0201c;hit and run&#x0201c; mechanism of beta HPV plus UV radiation in skin cancer development [<xref rid="B26-vaccines-12-01439" ref-type="bibr">26</xref>].</p><p>On the other hand, a recent study of Strickley et al. showed that beta HPVs, as part of the human skin virome, may have beneficial effects for the host. Beta HPVs induce T-cell immunity that is also directed against virus-infected dysplastic keratinocytes, and thus may protect against cSCC development [<xref rid="B59-vaccines-12-01439" ref-type="bibr">59</xref>]. In the context of immunosuppression or immunosenescence, however, reduced T-cell mediated immunity may fail to eliminate HPV-infected keratinocytes and facilitate skin carcinogenesis in cooperation with UV radiation. This hypothesis is supported by experiments using the MmuPV1 mouse papillomavirus back skin model, where virus-infected mice develop fewer skin tumors than non-infected mice after exposure to chemical carcinogens or UV radiation. The protective effect was mediated by CD8+ tissue resident memory T cells (T<sub>RM</sub>). Moreover, beta HPV-reactive T<sub>RM</sub> (anti E7) were also detected in normal human skin, indicating adaptive immunity against commensal HPVs in healthy adults [<xref rid="B59-vaccines-12-01439" ref-type="bibr">59</xref>]. These epithelial T<sub>RM</sub> cells may protect against beta HPV-induced wart development, but also control beta HPV-infected cells undergoing UV-induced transformation, and thus suppress formation of cSCC. Under immunosuppression, increasing viral burden (increasing viral load and/or multiplicity of HPV types), possibly due to reduced T<sub>RM</sub> mediated immunity, becomes pro-carcinogenic in cooperation with UV radiation. The impairment of T<sub>RM</sub>-mediated protection against HPV-infected and -transformed keratinocytes may result in escape of dysplastic cells, in particular those that are not HPV-infected, providing an explanation for the fact that HPV DNA is less frequently detected in cancer cells of cSCC.</p><p>Whatever the role of beta HPV is in human epithelial cancer, being a constituent of the human skin microbiome that promotes development of local immune functions, or being an oncogenic factor for epithelial cancer, or both, the enhancement of immune functions directed against virus-infected keratinocytes, which potentially may become dysplastic either by viral activities or other factors, would be an obvious approach to prevent the development of epithelial cancers. Strengthening of immune reactions against beta HPVs may be achieved by prophylactic and therapeutic vaccination against these HPV types. This is of particular importance in immunosuppressed patients that have a much higher risk of tumor development, and ideally should by applied prior to immunosuppression.</p></sec></sec><sec id="sec4-vaccines-12-01439"><title>4. Therapeutic Interventions to Inhibit HPV-Associated Cutaneous Diseases</title><p>Any interaction with the expression or activity of HPV oncogenes may be exploited for therapeutic intervention to inhibit HPV carcinogenesis. Potential interventions directed against mucosal and cutaneous HPV, including both prophylactic and therapeutic approaches, are shown in <xref rid="vaccines-12-01439-f001" ref-type="fig">Figure 1</xref>. Thus far, few compounds have been identified that inhibit HPV oncogenes and that might be considered as antivirals. Other therapeutic strategies targeting E6 and E7 oncoproteins include antisense RNA and DNA molecules [<xref rid="B60-vaccines-12-01439" ref-type="bibr">60</xref>], ribozymes targeted against HPV oncogene transcripts [<xref rid="B61-vaccines-12-01439" ref-type="bibr">61</xref>], and methods of silencing E6 and E7 gene expression [<xref rid="B62-vaccines-12-01439" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-01439" ref-type="bibr">63</xref>]. However, all these approaches are still in an early development phase, and translation into clinical practice may be affected by safety issues.</p><p>More advanced approaches to inhibit HPV-induced disorders are represented by vaccination strategies. Currently, three vaccines consisting of L1-VLPs are licensed [<xref rid="B64-vaccines-12-01439" ref-type="bibr">64</xref>]. They are directed against HPV 16 and 18 (Cervarix), HPV 6, 11, 16, and 18 (Gardasil) and HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (Gardasil-9), respectively, and efficiently prevent anogenital tumors caused by the targeted HPV types due to the induction of neutralizing antibodies [<xref rid="B5-vaccines-12-01439" ref-type="bibr">5</xref>,<xref rid="B7-vaccines-12-01439" ref-type="bibr">7</xref>,<xref rid="B65-vaccines-12-01439" ref-type="bibr">65</xref>]. These vaccines, however, are largely type-specific, providing no or low cross-protection against other HPV types, in particular beta HPVs [<xref rid="B66-vaccines-12-01439" ref-type="bibr">66</xref>], and show limited efficiency in immunosuppressed patients [<xref rid="B27-vaccines-12-01439" ref-type="bibr">27</xref>]. Regarding vaccination against beta HPVs, it must be considered that in contrast to alpha HPVs, no high-risk beta HPVs have been identified. Instead, a broad spectrum of beta HPVs is detected in AK and cSCC, with no specific types dominating, requiring coverage of a large number of different HPV types. As beta HPV infection occurs soon after birth, preventive vaccination must be very early in life. However, considering the potential beneficial effects of beta HPV infection, the prevention of beta HPV infection may be even disadvantageous. On the other hand, therapeutic vaccination to boost antiviral immunity may be more effective to prevent skin tumor formation, as it is directed against virus-infected cells in precancerous lesions.</p><sec id="sec4dot1-vaccines-12-01439"><title>4.1. Management of HPV-Associated Cutaneous Lesions with Licensed HPV Vaccines</title><p>Since the efficacy of VLP-based vaccines is based mainly on induction of neutralizing antibodies preventing primary infection, they were not recommended to treat prevalent HPV infection [<xref rid="B67-vaccines-12-01439" ref-type="bibr">67</xref>]. Treatment of existing HPV infection rather requires therapeutic vaccines that target E6 and E7 proteins, which are constantly expressed in infected cells. Nevertheless, L1-VLP vaccines have been used to manage different lesions with active or pre-existent HPV infection. Indeed, there are some reports on successful treatment of cutaneous warts and genital warts with HPV L1-VLPs [<xref rid="B68-vaccines-12-01439" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-12-01439" ref-type="bibr">69</xref>].</p><p>For instance, Shin et al. reported 62.2% complete clearance of recalcitrant cutaneous warts after application of Gardasil-9 [<xref rid="B70-vaccines-12-01439" ref-type="bibr">70</xref>]. Other studies, however, showed a lack of efficacy of both quadrivalent and nonavalent vaccines in the majority of patients with verruca vulgaris [<xref rid="B71-vaccines-12-01439" ref-type="bibr">71</xref>]. Similarly, several studies reported on clinical responses of patients with anogenital warts treated with the bi-, quadri-, or nonavalent vaccine [<xref rid="B72-vaccines-12-01439" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-12-01439" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-12-01439" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-12-01439" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-12-01439" ref-type="bibr">76</xref>]. In a study comparing standard therapy (cryotherapy, nitrizinc complex, Imiquimod 5%, or PDT) and combined therapy (standard therapy plus vaccination with Gardasil-9) for treatment of anogenital and oral warts, clinical response (complete or partial clearance) was significantly higher in patients receiving combined therapy [<xref rid="B72-vaccines-12-01439" ref-type="bibr">72</xref>]. As with cutaneous warts, lack of efficiency of HPV vaccines in treatment of genital warts was also reported [<xref rid="B77-vaccines-12-01439" ref-type="bibr">77</xref>]. In a large study including &#x0003e;500 patients with genital warts receiving the quadrivalent HPV vaccine or placebo in addition to topical treatment (imiquimod or podophyllotoxin), no benefit of the HPV vaccine was demonstrated [<xref rid="B78-vaccines-12-01439" ref-type="bibr">78</xref>]. Whereas in a few studies no wart recurrence after successful treatment with HPV vaccines was observed [<xref rid="B79-vaccines-12-01439" ref-type="bibr">79</xref>], a large register-based study from Norway showed that administration of a quadrivalent HPV vaccine after the first manifestation of anogenital warts did not prevent subsequent disease episodes, indicating no protection of the vaccines against recurrent disease [<xref rid="B80-vaccines-12-01439" ref-type="bibr">80</xref>].</p><p>In addition, successful treatment of keratinocyte carcinomas using the quadrivalent and nonavalent Gardasil vaccine has also been reported [<xref rid="B81-vaccines-12-01439" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-12-01439" ref-type="bibr">82</xref>]. By screening registry data of patients under immunosuppressive treatment for transplantation or autoimmune disease and patients with cancer and chemotherapy that had received three doses of Gardasil-9, a significant decrease in dermatologic procedures related to skin cancer was noticed in immunosuppressed patients after administration of the vaccine, indicating Gardasil-9 vaccination may decrease tumor burden in these patients [<xref rid="B83-vaccines-12-01439" ref-type="bibr">83</xref>]. Gardasil-9 was also applied in patients with AK. In a case series of 12 immunocompetent patients with high AK burden and insufficient response to previous conventional AK treatments, Gardasil-9 was administered at month 0, 2, and 6 in addition to conventional AK therapies. Twelve months after the beginning of vaccination, the total number of AK lesions was reduced by 85% on an average [<xref rid="B84-vaccines-12-01439" ref-type="bibr">84</xref>]. However, it is unclear to what extent Gardasil-9 vaccination contributed to the clinical response, as the case series did not include a control group receiving conventional therapy only.</p><p>Genital warts are caused mainly by HPV types 6 and 11, which were covered in the quadrivalent and nonavalent HPV vaccines. Although HPV infection is already established in genital warts, antibodies induced by vaccination may neutralize virus particles resulting from virus replication and prevent ongoing productive infection in the mucosal epithelium. In contrast, HPV types mostly associated with cutaneous warts, AK, and KC are not specifically targeted by the licensed HPV vaccines. The therapeutic effect in these cases may result from antigenic similarity of the L1 capsid proteins or, more likely, by nonspecific immune stimulation induced by the adjuvants in the vaccine formulations. Administration of the quadrivalent HPV vaccine in an immunosuppressed female patient with WILD syndrome (warts, immunodeficiency, lymphoedema, and anogenital dysplasia), presenting with both cutaneous and genital warts, resulted in regression of cutaneous warts but not genital warts. None of the HPV types covered by the vaccine was detected in cutaneous warts, whereas HPV 6 was found in the genital warts [<xref rid="B85-vaccines-12-01439" ref-type="bibr">85</xref>]. The clinical response of cutaneous warts only indicate that the adjuvant of the vaccine may be more important than the HPV specific constituents for the clinical response in lesions with active HPV infection.</p></sec><sec id="sec4dot2-vaccines-12-01439"><title>4.2. Next Generation VLP-Based Vaccines for Beta HPV-Associated Skin Cancer</title><p>Due to the large number of different beta HPV types detected in skin cancers, with no particular type predominating, and considering that these cancers occur mainly in older and immunosuppressed patients, a vaccine with broad protecting activity is required that is effective in immunocompromised individuals and those already infected with beta HPVs.</p><p>Using the <italic toggle="yes">Mastomys natalensis</italic> PV (MnPV)/<italic toggle="yes">Mastomys coucha</italic> mouse model, Vinz&#x000f3;n et al. showed that vaccination with L1-VLP-based vaccines against MnPV prevented formation of skin tumors in both healthy and immunocompromised animals [<xref rid="B86-vaccines-12-01439" ref-type="bibr">86</xref>]. Moreover, in animals already infected with MnPV, vaccination caused maintenance of a low viral load and prevented virus spread and tumor formation [<xref rid="B86-vaccines-12-01439" ref-type="bibr">86</xref>]. The study thus provided strong evidence that, in principle, vaccination should be feasible to prevent HPV-associated skin tumors in humans, even under immunosuppression. L1-VLPs, however, are largely type-specific, and thus impractical for use against the diverse group of beta HPVs found in human KC, as a sufficiently multivalent L1-VLP vaccine covering the more than 50 beta HPV types is technically difficult to realize.</p><p>In contrast to L1-VLPs, peptides derived from the minor capsid protein L2 or recombinantly expressed full length L2 were shown to generate a broad range of cross reactivity due to highly conserved regions among HPV types [<xref rid="B87-vaccines-12-01439" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-12-01439" ref-type="bibr">88</xref>]. In a large-scale analysis of HPV16 L2 gene sequences from different geographic areas, the conservation of N-terminal L2 specific epitopes was confirmed [<xref rid="B89-vaccines-12-01439" ref-type="bibr">89</xref>]. No amino acid changes were detected in the region aa17-36 used for vaccination. A variation adjacent to that epitope (D43E) was identified; however, it is not known whether it affects the tertiary structure of the L2 protein. Furthermore, antibody titers induced by L2 antigens are significantly lower compared to L1-VLPs [<xref rid="B90-vaccines-12-01439" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-12-01439" ref-type="bibr">91</xref>]. Several strategies have been utilized to improve immunogenicity of L2, as for instance the use of concatemers [<xref rid="B88-vaccines-12-01439" ref-type="bibr">88</xref>,<xref rid="B92-vaccines-12-01439" ref-type="bibr">92</xref>], fusion of L2 peptides to highly immunogenic compounds, like bacterial flagellin or thioredoxin [<xref rid="B93-vaccines-12-01439" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-12-01439" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-12-01439" ref-type="bibr">95</xref>], insertion of L2 peptides in heterologous virus capsids, like <italic toggle="yes">adeno-associated virus</italic> (AAV), <italic toggle="yes">adenovirus</italic> or bacteriophages [<xref rid="B96-vaccines-12-01439" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-12-01439" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-12-01439" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-12-01439" ref-type="bibr">99</xref>], <italic toggle="yes">Lactobacillus</italic>-based recombinant vaccines [<xref rid="B100-vaccines-12-01439" ref-type="bibr">100</xref>], or chimeric vaccines consisting of the HPV L2 peptide RG1 (aa 17-36) in mucosal HPV L1-VLPs [<xref rid="B101-vaccines-12-01439" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-12-01439" ref-type="bibr">102</xref>].</p><p>A vaccine of HPV16 RG1 inserted into the HPV16 L1 DE-surface loop, which contains the immunodominant neutralizing epitopes, induces cross-neutralizing antibodies to other mucosal HPVs and also some beta HPV types. The additional RG1 epitope did not affect HPV 16 L1-specific immune responses (high antibody titers and cytotoxic T cells to HPV 16) [<xref rid="B103-vaccines-12-01439" ref-type="bibr">103</xref>]. Thus, the vaccine combines HPV16-specific immunogenicity based on L1-VLP and broad-spectrum immunogenicity based on L2. Currently, the HPV16 VLP-HPV16 RG1 is produced under cGMP (current good manufacturing practice) and tested in a Phase I study as potential vaccine candidate (Pathovax LLC) [<xref rid="B104-vaccines-12-01439" ref-type="bibr">104</xref>].</p><p>In addition, the HPV16 VLP-HPV16 RG1 and another novel L2-based vaccine candidate (CUT-PANHPVAX) were recently investigated in the <italic toggle="yes">M. coucha</italic> natural infection model [<xref rid="B105-vaccines-12-01439" ref-type="bibr">105</xref>]. CUT-PANHPVAX represents a fusion protein of L2 peptides (aa20-38) from HPV types 1, 2, 3, 4, 14, 15, 22, 36, 41, 76, 88, and 95, respectively, inserted into the thioredoxin scaffold of <italic toggle="yes">Pyrococcus furiosus</italic> and fused to the OVX313 oligomerization domain (a hybrid derivative of the complement inhibitor C4-binding protein), which allows assembly to heat-stable heptamers [<xref rid="B106-vaccines-12-01439" ref-type="bibr">106</xref>]. Both vaccines induced robust cross-reactive and -protective antibodies against MnPV L2 that prevent development of MnPV-induced skin tumors [<xref rid="B105-vaccines-12-01439" ref-type="bibr">105</xref>]. Nevertheless, reactivity against L2 differs among both vaccines, as HPV16 RG1 VLP shows weaker cross neutralization of MnPV pseudovirions than CUT-PANHPVAX, indicating lesser cross-protection against other HPVs [<xref rid="B105-vaccines-12-01439" ref-type="bibr">105</xref>]. The limitation to induce broad cross-protection against other HPV types probably results from lower sequence identity of the RG1 epitope of mucosal and cutaneous HPVs. Indeed, when combining the RG1 epitope of HPV16 with beta HPV RG1 displayed within the L1 DE loop of HPV16 and HPV18, a better cross-neutralization potential for cutaneous HPV was achieved [<xref rid="B101-vaccines-12-01439" ref-type="bibr">101</xref>,<xref rid="B107-vaccines-12-01439" ref-type="bibr">107</xref>].</p></sec><sec id="sec4dot3-vaccines-12-01439"><title>4.3. Therapeutic Vaccination Against Viral Oncoproteins</title><p>L1-VLP vaccines induce long-lasting high antibody titers and provide long-term protection, but they do not impact pre-existing HPV infection, probably because the basal keratinocytes harboring the viral infection do not express capsid antigens at detectable levels, and therefore are not attacked by vaccine-induced antibodies, whereas the infected cells in the upper epithelial layers that do express capsid antigens will be sloughed off shortly by desquamation. Thus, L1-VLPs essentially do not have therapeutic potential and are restricted to prophylaxis primarily. Therapeutic vaccines against HPVs usually target products of viral early genes, mainly the oncogenes, E6 and E7, which are obligatorily expressed in all HPV-infected cells [<xref rid="B108-vaccines-12-01439" ref-type="bibr">108</xref>]. Such vaccines are designed to activate HPV specific cytotoxic T cells and T-Helper cells to kill HPV-infected cells [<xref rid="B109-vaccines-12-01439" ref-type="bibr">109</xref>]. Vaccines based on E2 antigen are also of interest. As a negative regulator of E6 and E7, E2 expression in precancerous lesions is higher than E6 and E7. In addition, E2 is required for HPV replication, so that E2 vaccines may be used for the treatment of precancerous lesions and genital warts [<xref rid="B110-vaccines-12-01439" ref-type="bibr">110</xref>].</p><p>Different strategies have been used to develop therapeutic vaccines against HPV, including live vector-based vaccines (bacterial- or viral-based), peptide- and protein-based vaccines, nucleic acid-based vaccines, and whole cell vaccines [<xref rid="B108-vaccines-12-01439" ref-type="bibr">108</xref>]. In another approach, activation of innate immunity was shown to induce adaptive immune responses, preventing the development of skin cancer [<xref rid="B111-vaccines-12-01439" ref-type="bibr">111</xref>]. Using a HPV8 transgenic mouse model the treatment with poly (I:C) (polyinosinic-polycytidylic acid) which binds to melanoma differentiation-associated protein 5 (MDA5) and Toll-like receptor (TLR) 3, similar to viral nucleic acids, induces a T-cell response directed against viral antigen expressing cells in the skin. These T cells most likely represent tissue resident memory T cells and are required to prevent tumor formation. The technique corresponds to an autovaccination procedure with the advantage of activating adaptive immunity against beta HPV types that are present in the skin, but do not need to be specified.</p><p>Whole cell vaccines include dendritic cells (DCs) obtained from patients that are in vitro stimulated with HPV antigens or transfected with vectors expressing HPV antigens, then transferred back to patients. The safety and immunogenicity of DCs pulsed with HPV16/18 E7 antigen have been shown in patients with cervical cancer [<xref rid="B112-vaccines-12-01439" ref-type="bibr">112</xref>]. However, DC-based vaccines are difficult to produce on a large scale and different processing methods may affect vaccine quality.</p><p>Vector-based vaccines include attenuated bacteria, like <italic toggle="yes">Listeria monocytogenes</italic> or replication-deficient viruses, like AAV, <italic toggle="yes">adenovirus</italic>, or <italic toggle="yes">vaccinia virus</italic>, that carry genes for HPV-specific antigens to replicate in host cells and induce an immune response against HPV. Despite inducing strong immune responses and promising results in some phase I/II studies, the use of these vaccines may be limited by safety issues, in particular in immunocompromised patients [<xref rid="B113-vaccines-12-01439" ref-type="bibr">113</xref>].</p><p>In contrast, protein/peptide and DNA vaccines are generally safer, but on the other hand are less immunogenic, requiring adjuvants or immunostimulatory molecules to increase immunogenicity. Joined peptides of HPV E6 and E7, covering the complete sequence of both oncogenes and emulsified with the adjuvant Montanide ISA-51, were used to treat HPV16 positive cancers together with PD1 inhibitor nivolumab and resulted in a higher response rate compared to nivolumab alone [<xref rid="B114-vaccines-12-01439" ref-type="bibr">114</xref>]. The vaccine alone, however, did not affect regression of cervical cancer, probably because vaccine-activated T cells are inhibited by an immunosuppressive tumor microenvironment [<xref rid="B115-vaccines-12-01439" ref-type="bibr">115</xref>]. In another study, heat-shock protein (HSP) 110 was used as an adjuvant to enhance the immune response of cytotoxic T cells (CTL) directed against HPV16 E7 epitopes. In a mouse model, immunized animals induced a strong CTL response and inhibited the growth of established tumors [<xref rid="B116-vaccines-12-01439" ref-type="bibr">116</xref>].</p><p>Immunogenicity was also significantly improved by fusing HPV16 and HPV18 full length E7 to the TLR4 agonist fibronectin extra domain A (EDA) to direct the antigen to dendritic cells. In combination with TLR3 agonists Poly (I:C) and Poly-ICLC, the recombinant E7-EDA protein induced E7-specific CTL responses and eliminated established genital or subcutaneous HPV16 tumors in mice with high efficiency [<xref rid="B117-vaccines-12-01439" ref-type="bibr">117</xref>].</p><p>Like L1-VLPs, L2-based vaccines also do not have therapeutic potential, but they may induce both prophylactic and therapeutic immunity when fused with the HPV oncoproteins E6 and E7. Such fusion proteins might be particularly useful for vaccination against beta HPVs to which most patients of interest have already been exposed, as beta HPVs are acquired early in childhood [<xref rid="B118-vaccines-12-01439" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-01439" ref-type="bibr">119</xref>]. An example for this strategy is represented by TA-CIN (tissue antigen&#x02013;cervical intraepithelial neoplasia), a fusion protein of HPV16 L2, E6 and E7, which is able induce antibodies and T-cell responses and was shown to provide both prophylactic and therapeutic activity in a pre-clinical mouse model [<xref rid="B120-vaccines-12-01439" ref-type="bibr">120</xref>]. The immunogenicity of TA-CIN was subsequently verified in clinical studies and confirmed induction of humoral and cellular immune responses in humans [<xref rid="B121-vaccines-12-01439" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-12-01439" ref-type="bibr">122</xref>].</p><p>In a similar approach, a fusion protein of HPV6 E7 and L2 was used to treat HPV6 caused genital warts. Induction of humoral and T-cell responses against L2 and E7, respectively, was shown in clinical studies [<xref rid="B123-vaccines-12-01439" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-12-01439" ref-type="bibr">124</xref>]. However, therapeutic vaccination failed to increase the efficacy of conventional therapies in a study of 457 subjects with anogenital warts that received the vaccine or placebo, in combination with ablative therapy or podophyllotoxin, possibly due to the frequent spontaneous regression of genital warts and the large proportion with multiple HPV types [<xref rid="B125-vaccines-12-01439" ref-type="bibr">125</xref>].</p><p>DNA vaccines usually represent recombinant bacterial plasmids encoding the antigens of interest under control of high-efficiency eukaryotic promoters. After injection DNA vaccines must enter the nucleus of eucaryotic cells to induce expression of antigens, which are then presented by MHC class I molecules to activate the immune system. The inability of the DNA to amplify by itself results in poor immunogenicity of DNA vaccines and requires the use of strong adjuvants or immunostimulatory substances. Vaccination of mice with a DNA vaccine composed of HPV16 L2, E6, and E7 linked to calreticulin (CRT) was shown to induce E6- and E7-specific CD8+ T cells that conferred significant anti-tumor effects against E6/E7-expressing tumors and an L2-specific protective antibody response against HPV16 was demonstrated [<xref rid="B126-vaccines-12-01439" ref-type="bibr">126</xref>]. The vaccination approach was also tested in the MmuPV1 model using hCRT-MmuPV1-E6-E7-L2 and induced CTL responses against E6 and E7 and anti L2-antibodies [<xref rid="B127-vaccines-12-01439" ref-type="bibr">127</xref>]. Whereas the vaccine causes disappearance of persistent papillomas in treated mice, it is unclear whether it confers protection against formation of tumors associated with human PV types.</p><p>Another vaccine strategy based on nucleic acids is represented by mRNA vaccines. Compared to DNA vaccines, self-amplifying mRNA vaccines have the capacity for autonomous replication, and as ligands of TLR7 and TLR8, they may be considered natural adjuvants that can induce strong immune responses [<xref rid="B128-vaccines-12-01439" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-12-01439" ref-type="bibr">129</xref>]. Thus far, mRNA vaccines are not well studied to protect against HPV infections and diseases. However, with the outbreak of the new coronavirus in 2020, these vaccines experienced significant improvements regarding safety and efficiency, and therefore mRNA vaccines are likely to be developed for HPV in the future.</p></sec></sec><sec id="sec5-vaccines-12-01439"><title>5. Concluding Remarks</title><p>Many of the described candidates for therapeutic vaccination of HPV were studied in clinical phase I, II, and III trials. Although they were successful in animal models, there are concerns of limited clinical efficiency in human HPV-associated tumors. Indeed, it is important to consider that immunosuppressive microenvironments of human tumors, characterized by immunosuppressive cytokines and immunosuppressive cells like M2 macrophages, myeloid derived suppressor cells (MDSC), or cancer-associated fibroblasts (CAF), may affect the efficacy of vaccine-induced T cells [<xref rid="B130-vaccines-12-01439" ref-type="bibr">130</xref>]. Therefore, it is a primary goal of cancer therapy to reverse the immunosuppressive tumor-promoting environment into an immune-activating, tumor-destroying milieu. In addition, immunogenicity of HPV vaccines needs to be improved further. A promising strategy is represented by mRNA vaccines, encapsulated in cationic lipid nanoparticles, which are highly immunogenic due to their mRNA content and the use of lipid nanoparticles, both representing natural adjuvants. The combination of therapeutic vaccination with immune checkpoint inhibitors to reverse immunosuppression of cytotoxic T cells is another strategy [<xref rid="B131-vaccines-12-01439" ref-type="bibr">131</xref>]. Indeed, anti PD-1 antibodies pembrolizumab and nivolumab, have shown some effectiveness in combination with HPV vaccines [<xref rid="B132-vaccines-12-01439" ref-type="bibr">132</xref>]. However, in contrast to the three licensed VLP-based prophylactic vaccines against alpha HPVs, none of the vaccine candidates for beta HPVs have thus far been approved for application in humans.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, T.M. and E.S.; methodology, T.M. and E.S.; writing&#x02014;original draft preparation, T.M.; writing&#x02014;review and editing, E.S.; visualization, T.M.; supervision, E.S.; project administration, E.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01439"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zur Hausen</surname><given-names>H.</given-names></name>
</person-group><article-title>Papillomaviruses and cancer: From basic studies to clinical application</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nrc798</pub-id><pub-id pub-id-type="pmid">12044010</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01439"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grce</surname><given-names>M.</given-names></name>
<name><surname>Mravak-Stipetic</surname><given-names>M.</given-names></name>
</person-group><article-title>Human papillomavirus-associated diseases</article-title><source>Clin. Dermatol.</source><year>2014</year><volume>32</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.clindermatol.2013.10.006</pub-id><pub-id pub-id-type="pmid">24559561</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01439"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaccarella</surname><given-names>S.</given-names></name>
<name><surname>Herrero</surname><given-names>R.</given-names></name>
<name><surname>Dai</surname><given-names>M.</given-names></name>
<name><surname>Snijders</surname><given-names>P.J.</given-names></name>
<name><surname>Meijer</surname><given-names>C.J.</given-names></name>
<name><surname>Thomas</surname><given-names>J.O.</given-names></name>
<name><surname>Hoang Anh</surname><given-names>P.T.</given-names></name>
<name><surname>Ferreccio</surname><given-names>C.</given-names></name>
<name><surname>Matos</surname><given-names>E.</given-names></name>
<name><surname>Posso</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Reproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC HPV prevalence surveys</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2006</year><volume>15</volume><fpage>2148</fpage><lpage>2153</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0556</pub-id><pub-id pub-id-type="pmid">17119039</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01439"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouvard</surname><given-names>V.</given-names></name>
<name><surname>Baan</surname><given-names>R.</given-names></name>
<name><surname>Straif</surname><given-names>K.</given-names></name>
<name><surname>Grosse</surname><given-names>Y.</given-names></name>
<name><surname>Secretan</surname><given-names>B.</given-names></name>
<name><surname>El Ghissassi</surname><given-names>F.</given-names></name>
<name><surname>Benbrahim-Tallaa</surname><given-names>L.</given-names></name>
<name><surname>Guha</surname><given-names>N.</given-names></name>
<name><surname>Freeman</surname><given-names>C.</given-names></name>
<name><surname>Galichet</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>A review of human carcinogens&#x02013;Part B: Biological agents</article-title><source>Lancet Oncol.</source><year>2009</year><volume>10</volume><fpage>321</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70096-8</pub-id><pub-id pub-id-type="pmid">19350698</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01439"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harper</surname><given-names>D.M.</given-names></name>
<name><surname>DeMars</surname><given-names>L.R.</given-names></name>
</person-group><article-title>HPV vaccines&#x02014;A review of the first decade</article-title><source>Gynecol. Oncol.</source><year>2017</year><volume>146</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2017.04.004</pub-id><pub-id pub-id-type="pmid">28442134</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01439"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hancock</surname><given-names>G.</given-names></name>
<name><surname>Hellner</surname><given-names>K.</given-names></name>
<name><surname>Dorrell</surname><given-names>L.</given-names></name>
</person-group><article-title>Therapeutic HPV vaccines</article-title><source>Best Pract. Res. Clin. Obstet. Gynaecol.</source><year>2018</year><volume>47</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.bpobgyn.2017.09.008</pub-id><pub-id pub-id-type="pmid">29108943</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01439"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiller</surname><given-names>J.T.</given-names></name>
<name><surname>Lowy</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Understanding and learning from the success of prophylactic human papillomavirus vaccines</article-title><source>Nat. Rev. Microbiol.</source><year>2012</year><volume>10</volume><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2872</pub-id><pub-id pub-id-type="pmid">22961341</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01439"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antonsson</surname><given-names>A.</given-names></name>
<name><surname>Karanfilovska</surname><given-names>S.</given-names></name>
<name><surname>Lindqvist</surname><given-names>P.G.</given-names></name>
<name><surname>Hansson</surname><given-names>B.G.</given-names></name>
</person-group><article-title>General acquisition of human papillomavirus infections of skin occurs in early infancy</article-title><source>J. Clin. Microbiol.</source><year>2003</year><volume>41</volume><fpage>2509</fpage><lpage>2514</lpage><pub-id pub-id-type="doi">10.1128/JCM.41.6.2509-2514.2003</pub-id><pub-id pub-id-type="pmid">12791874</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01439"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nanz</surname><given-names>L.</given-names></name>
<name><surname>Keim</surname><given-names>U.</given-names></name>
<name><surname>Katalinic</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>T.</given-names></name>
<name><surname>Garbe</surname><given-names>C.</given-names></name>
<name><surname>Leiter</surname><given-names>U.</given-names></name>
</person-group><article-title>Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>606</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16030606</pub-id><pub-id pub-id-type="pmid">38339357</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01439"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keim</surname><given-names>U.</given-names></name>
<name><surname>Katalinic</surname><given-names>A.</given-names></name>
<name><surname>Holleczek</surname><given-names>B.</given-names></name>
<name><surname>Wakkee</surname><given-names>M.</given-names></name>
<name><surname>Garbe</surname><given-names>C.</given-names></name>
<name><surname>Leiter</surname><given-names>U.</given-names></name>
</person-group><article-title>Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland</article-title><source>Eur. J. Cancer</source><year>2023</year><volume>183</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.01.017</pub-id><pub-id pub-id-type="pmid">36801607</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01439"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apalla</surname><given-names>Z.</given-names></name>
<name><surname>Lallas</surname><given-names>A.</given-names></name>
<name><surname>Sotiriou</surname><given-names>E.</given-names></name>
<name><surname>Lazaridou</surname><given-names>E.</given-names></name>
<name><surname>Ioannides</surname><given-names>D.</given-names></name>
</person-group><article-title>Epidemiological trends in skin cancer</article-title><source>Dermatol. Pract. Concept.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.5826/dpc.0702a01</pub-id><pub-id pub-id-type="pmid">28515985</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01439"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Black</surname><given-names>J.O.</given-names></name>
</person-group><article-title>Xeroderma pigmentosum</article-title><source>Head Neck Pathol.</source><year>2016</year><volume>10</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s12105-016-0707-8</pub-id><pub-id pub-id-type="pmid">26975629</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01439"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bresler</surname><given-names>S.C.</given-names></name>
<name><surname>Padwa</surname><given-names>B.L.</given-names></name>
<name><surname>Granter</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Nevoid basal cell carcinoma syndrome (Gorlin syndrome)</article-title><source>Head Neck Pathol.</source><year>2016</year><volume>10</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1007/s12105-016-0706-9</pub-id><pub-id pub-id-type="pmid">26971503</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01439"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lazarczyk</surname><given-names>M.</given-names></name>
<name><surname>Cassonnet</surname><given-names>P.</given-names></name>
<name><surname>Pons</surname><given-names>C.</given-names></name>
<name><surname>Jacob</surname><given-names>Y.</given-names></name>
<name><surname>Favre</surname><given-names>M.</given-names></name>
</person-group><article-title>The EVER proteins as a natural barrier against papillomaviruses: A new insight into the pathogenesis of human papillomavirus infections</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2009</year><volume>73</volume><fpage>348</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00033-08</pub-id><pub-id pub-id-type="pmid">19487731</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01439"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>B.K.</given-names></name>
<name><surname>Kricker</surname><given-names>A.</given-names></name>
</person-group><article-title>The epidemiology of UV induced skin cancer</article-title><source>J. Photochem. Photobiol.</source><year>2001</year><volume>63</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S1011-1344(01)00198-1</pub-id><pub-id pub-id-type="pmid">11684447</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01439"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>C.</given-names></name>
<name><surname>Bajdik</surname><given-names>C.D.</given-names></name>
<name><surname>Willemze</surname><given-names>R.</given-names></name>
<name><surname>De Gruijl</surname><given-names>F.R.</given-names></name>
<name><surname>Bavinck</surname><given-names>J.N.B.</given-names></name>
</person-group><article-title>The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer</article-title><source>J. Investig. Dermatol.</source><year>2003</year><volume>120</volume><fpage>1087</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2003.12246.x</pub-id><pub-id pub-id-type="pmid">12787139</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01439"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nindl</surname><given-names>I.</given-names></name>
<name><surname>R&#x000f6;sl</surname><given-names>F.</given-names></name>
</person-group><article-title>Molecular concepts of virus infections causing skin cancer in organ transplant recipients</article-title><source>Am. J. Transplant.</source><year>2008</year><volume>8</volume><fpage>2199</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02392.x</pub-id><pub-id pub-id-type="pmid">18785959</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01439"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Euvrard</surname><given-names>S.</given-names></name>
<name><surname>Kanitakis</surname><given-names>J.</given-names></name>
<name><surname>Claudy</surname><given-names>A.</given-names></name>
</person-group><article-title>Skin cancers after organ transplantation</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1056/NEJMra022137</pub-id><pub-id pub-id-type="pmid">12711744</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01439"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harwood</surname><given-names>C.A.</given-names></name>
<name><surname>Toland</surname><given-names>A.E.</given-names></name>
<name><surname>Proby</surname><given-names>C.M.</given-names></name>
<name><surname>Euvrard</surname><given-names>S.</given-names></name>
<name><surname>Hofbauer</surname><given-names>G.F.L.</given-names></name>
<name><surname>Tommasino</surname><given-names>M.</given-names></name>
<name><surname>Bavinck</surname><given-names>J.N.B.</given-names></name>
<collab>KeraCon Consortium</collab>
</person-group><article-title>The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients</article-title><source>Br. J. Dermatol.</source><year>2017</year><volume>177</volume><fpage>1217</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1111/bjd.15956</pub-id><pub-id pub-id-type="pmid">29086420</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01439"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proby</surname><given-names>C.M.</given-names></name>
<name><surname>Harwood</surname><given-names>C.A.</given-names></name>
<name><surname>Neale</surname><given-names>R.E.</given-names></name>
<name><surname>Green</surname><given-names>A.C.</given-names></name>
<name><surname>Euvrard</surname><given-names>S.</given-names></name>
<name><surname>Naldi</surname><given-names>L.</given-names></name>
<name><surname>Tessari</surname><given-names>G.</given-names></name>
<name><surname>Feltkamp</surname><given-names>M.C.</given-names></name>
<name><surname>de Koning</surname><given-names>M.N.</given-names></name>
<name><surname>Quint</surname><given-names>W.G.</given-names></name>
<etal/>
</person-group><article-title>A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients</article-title><source>Am. J. Transplant.</source><year>2011</year><volume>11</volume><fpage>1498</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03589.x</pub-id><pub-id pub-id-type="pmid">21718442</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01439"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ulrich</surname><given-names>C.</given-names></name>
<name><surname>Kanitakis</surname><given-names>J.</given-names></name>
<name><surname>Stockfleth</surname><given-names>E.</given-names></name>
<name><surname>Euvrard</surname><given-names>S.</given-names></name>
</person-group><article-title>Skin cancer in organ transplant recipients&#x02014;Where do we stand today?</article-title><source>Am. J. Transplant.</source><year>2008</year><volume>8</volume><fpage>2192</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02386.x</pub-id><pub-id pub-id-type="pmid">18782290</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01439"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Doorslaer</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Bernard</surname><given-names>H.U.</given-names></name>
<name><surname>Chan</surname><given-names>P.K.S.</given-names></name>
<name><surname>De Salle</surname><given-names>R.</given-names></name>
<name><surname>Dillner</surname><given-names>J.</given-names></name>
<name><surname>Forslund</surname><given-names>O.</given-names></name>
<name><surname>Haga</surname><given-names>T.</given-names></name>
<name><surname>McBride</surname><given-names>A.A.</given-names></name>
<name><surname>Villa</surname><given-names>L.L.</given-names></name>
<etal/>
</person-group><article-title>ICTV Virus Taxonomy Profile: <italic toggle="yes">Papillomaviridae</italic></article-title><source>J. Gen. Virol.</source><year>2018</year><volume>99</volume><fpage>989</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.001105</pub-id><pub-id pub-id-type="pmid">29927370</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01439"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Villiers</surname><given-names>E.M.</given-names></name>
<name><surname>Fauquet</surname><given-names>C.</given-names></name>
<name><surname>Broker</surname><given-names>T.R.</given-names></name>
<name><surname>Bernard</surname><given-names>H.U.</given-names></name>
<name><surname>zur Hausen</surname><given-names>H.</given-names></name>
</person-group><article-title>Classification of papillomaviruses</article-title><source>Virology</source><year>2004</year><volume>324</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2004.03.033</pub-id><pub-id pub-id-type="pmid">15183049</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01439"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clifford</surname><given-names>G.</given-names></name>
<name><surname>Franceschi</surname><given-names>S.</given-names></name>
<name><surname>Diaz</surname><given-names>M.</given-names></name>
<name><surname>Mu&#x000f1;oz</surname><given-names>N.</given-names></name>
<name><surname>Villa</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>(Suppl. S3)</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.026</pub-id></element-citation></ref><ref id="B25-vaccines-12-01439"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egawa</surname><given-names>N.</given-names></name>
<name><surname>Doorbar</surname><given-names>J.</given-names></name>
</person-group><article-title>The low-risk papillomaviruses</article-title><source>Virus Res.</source><year>2017</year><volume>231</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.12.017</pub-id><pub-id pub-id-type="pmid">28040475</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01439"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howley</surname><given-names>P.M.</given-names></name>
<name><surname>Pfister</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Beta genus papillomaviruses and skin cancer</article-title><source>Virology</source><year>2015</year><volume>479&#x02013;480</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.02.004</pub-id></element-citation></ref><ref id="B27-vaccines-12-01439"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasche</surname><given-names>D.</given-names></name>
<name><surname>Vinz&#x000f3;n</surname><given-names>S.E.</given-names></name>
<name><surname>R&#x000f6;sl</surname><given-names>F.</given-names></name>
</person-group><article-title>Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>874</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.00874</pub-id><pub-id pub-id-type="pmid">29770129</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01439"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johansson</surname><given-names>H.</given-names></name>
<name><surname>Bzhalava</surname><given-names>D.</given-names></name>
<name><surname>Ekstrom</surname><given-names>J.</given-names></name>
<name><surname>Hultin</surname><given-names>E.</given-names></name>
<name><surname>Dillner</surname><given-names>J.</given-names></name>
<name><surname>Forslund</surname><given-names>O.</given-names></name>
</person-group><article-title>Metagenomic sequencing of &#x0201c;HPV-negative&#x0201d; condylomas detects novel putative HPV types</article-title><source>Virology</source><year>2013</year><volume>440</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.01.023</pub-id><pub-id pub-id-type="pmid">23522725</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01439"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Madupu</surname><given-names>R.</given-names></name>
<name><surname>Karaoz</surname><given-names>U.</given-names></name>
<name><surname>Nossa</surname><given-names>C.W.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Yooseph</surname><given-names>S.</given-names></name>
<name><surname>Yachimski</surname><given-names>P.S.</given-names></name>
<name><surname>Brodie</surname><given-names>E.L.</given-names></name>
<name><surname>Nelson</surname><given-names>K.E.</given-names></name>
<name><surname>Pei</surname><given-names>Z.</given-names></name>
</person-group><article-title>Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4786</fpage><lpage>4797</lpage><pub-id pub-id-type="doi">10.1128/JVI.00093-14</pub-id><pub-id pub-id-type="pmid">24522917</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01439"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mejlhede</surname><given-names>N.</given-names></name>
<name><surname>Pedersen</surname><given-names>B.V.</given-names></name>
<name><surname>Frisch</surname><given-names>M.</given-names></name>
<name><surname>Fomsgaard</surname><given-names>A.</given-names></name>
</person-group><article-title>Multiple human papilloma virus types in cervical infections: Competition or synergy?</article-title><source>APMIS</source><year>2010</year><volume>118</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0463.2010.2602.x</pub-id><pub-id pub-id-type="pmid">20477809</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01439"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doorbar</surname><given-names>J.</given-names></name>
<name><surname>Egawa</surname><given-names>N.</given-names></name>
<name><surname>Griffin</surname><given-names>H.</given-names></name>
<name><surname>Kranjec</surname><given-names>C.</given-names></name>
<name><surname>Murakami</surname><given-names>I.</given-names></name>
</person-group><article-title>Human papillomavirus molecular biology and disease association</article-title><source>Rev. Med. Virol.</source><year>2015</year><volume>25</volume><issue>(Suppl. S1)</issue><fpage>2</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1002/rmv.1822</pub-id><pub-id pub-id-type="pmid">25752814</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01439"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doorbar</surname><given-names>J.</given-names></name>
<name><surname>Quint</surname><given-names>W.</given-names></name>
<name><surname>Banks</surname><given-names>L.</given-names></name>
<name><surname>Bravo</surname><given-names>I.G.</given-names></name>
<name><surname>Stoler</surname><given-names>M.</given-names></name>
<name><surname>Broker</surname><given-names>T.R.</given-names></name>
<name><surname>Stanley</surname><given-names>M.A.</given-names></name>
</person-group><article-title>The biology and life-cycle of human papillomaviruses</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>(Suppl. S5)</issue><fpage>F55</fpage><lpage>F70</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.083</pub-id><pub-id pub-id-type="pmid">23199966</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01439"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>E.</given-names></name>
<name><surname>Freese</surname><given-names>U.K.</given-names></name>
<name><surname>Gissmann</surname><given-names>L.</given-names></name>
<name><surname>Mayer</surname><given-names>W.</given-names></name>
<name><surname>Roggenbuck</surname><given-names>B.</given-names></name>
<name><surname>Stremlau</surname><given-names>A.</given-names></name>
<name><surname>zur Hausen</surname><given-names>H.</given-names></name>
</person-group><article-title>Structure and transcription of human papillomavirus type 18 and 16 sequences in cervical carcinoma cells</article-title><source>Nature</source><year>1985</year><volume>314</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/314111a0</pub-id><pub-id pub-id-type="pmid">2983228</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01439"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>S.I.</given-names></name>
<name><surname>Constandinou-Williams</surname><given-names>C.</given-names></name>
<name><surname>Wen</surname><given-names>K.</given-names></name>
<name><surname>Young</surname><given-names>L.S.</given-names></name>
<name><surname>Roberts</surname><given-names>S.</given-names></name>
<name><surname>Murray</surname><given-names>P.G.</given-names></name>
<name><surname>Woodman</surname><given-names>C.B.</given-names></name>
</person-group><article-title>Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: A longitudinal cohort study</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><fpage>3828</fpage><lpage>3832</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3099</pub-id><pub-id pub-id-type="pmid">19401452</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01439"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moody</surname><given-names>C.A.</given-names></name>
<name><surname>Laimins</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Human papillomavirus oncoproteins: Pathways to transformation</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>550</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1038/nrc2886</pub-id><pub-id pub-id-type="pmid">20592731</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01439"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prabhakar</surname><given-names>A.T.</given-names></name>
<name><surname>Morgan</surname><given-names>I.M.</given-names></name>
</person-group><article-title>A new role for human papillomavirus 16 E2: Mitotic activation of the DNA damage response to promote viral genome segregation</article-title><source>Tumour Virus Res.</source><year>2024</year><volume>18</volume><fpage>200291</fpage><pub-id pub-id-type="doi">10.1016/j.tvr.2024.200291</pub-id><pub-id pub-id-type="pmid">39245413</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01439"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skelin</surname><given-names>J.</given-names></name>
<name><surname>Tomaic</surname><given-names>V.</given-names></name>
</person-group><article-title>Comparative analysis of alpha and beta HPV E6 oncoproteins: Insights into functional distinctions and divergent mechanisms of pathogenesis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2253</elocation-id><pub-id pub-id-type="doi">10.3390/v15112253</pub-id><pub-id pub-id-type="pmid">38005929</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01439"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venuti</surname><given-names>A.</given-names></name>
<name><surname>Paolini</surname><given-names>F.</given-names></name>
<name><surname>Nasir</surname><given-names>L.</given-names></name>
<name><surname>Corteggio</surname><given-names>A.</given-names></name>
<name><surname>Roperto</surname><given-names>S.</given-names></name>
<name><surname>Campo</surname><given-names>M.S.</given-names></name>
<name><surname>Borzacchiello</surname><given-names>G.</given-names></name>
</person-group><article-title>Papillomavirus E5: The smallest oncoprotein with many functions</article-title><source>Mol. Cancer</source><year>2011</year><volume>10</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-10-140</pub-id><pub-id pub-id-type="pmid">22078316</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01439"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raffa</surname><given-names>S.</given-names></name>
<name><surname>Mancini</surname><given-names>V.</given-names></name>
<name><surname>French</surname><given-names>D.</given-names></name>
<name><surname>Rollo</surname><given-names>F.</given-names></name>
<name><surname>Benevolo</surname><given-names>M.</given-names></name>
<name><surname>Giuliani</surname><given-names>E.</given-names></name>
<name><surname>Don&#x000e0;</surname><given-names>M.G.</given-names></name>
<name><surname>Ranieri</surname><given-names>D.</given-names></name>
<name><surname>Belleudi</surname><given-names>F.</given-names></name>
</person-group><article-title>The Expression of HPV-16 E5 Oncoprotein Impacts the Transcript Profiles of FGFR2 and EMT-Related Genes in Preneoplastic Anal Epithelium Lesions</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>12085</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252212085</pub-id><pub-id pub-id-type="pmid">39596152</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01439"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antonsson</surname><given-names>A.</given-names></name>
<name><surname>Erfurt</surname><given-names>C.</given-names></name>
<name><surname>Hazard</surname><given-names>K.</given-names></name>
<name><surname>Holmgren</surname><given-names>V.</given-names></name>
<name><surname>Simon</surname><given-names>M.</given-names></name>
<name><surname>Kataoka</surname><given-names>A.</given-names></name>
<name><surname>Hossain</surname><given-names>S.</given-names></name>
<name><surname>Hakangard</surname><given-names>C.</given-names></name>
<name><surname>Hansson</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents</article-title><source>J. Gen. Virol.</source><year>2003</year><volume>84</volume><fpage>1881</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1099/vir.0.18836-0</pub-id><pub-id pub-id-type="pmid">12810883</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01439"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viarisio</surname><given-names>D.</given-names></name>
<name><surname>Gissmann</surname><given-names>L.</given-names></name>
<name><surname>Tommasino</surname><given-names>M.</given-names></name>
</person-group><article-title>Human papillomaviruses and carcinogenesis: Well-established and novel models</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>26</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.07.014</pub-id><pub-id pub-id-type="pmid">28778034</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01439"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wendel</surname><given-names>S.O.</given-names></name>
<name><surname>Wallace</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Loss of genome fidelity: Beta HPVs and the DNA damage response</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>2250</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02250</pub-id><pub-id pub-id-type="pmid">29187845</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01439"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Jong</surname><given-names>S.J.</given-names></name>
<name><surname>Crequer</surname><given-names>A.</given-names></name>
<name><surname>Matos</surname><given-names>I.</given-names></name>
<name><surname>Hum</surname><given-names>D.</given-names></name>
<name><surname>Gunasekharan</surname><given-names>V.</given-names></name>
<name><surname>Lorenzo</surname><given-names>L.</given-names></name>
<name><surname>Jabot-Hanin</surname><given-names>F.</given-names></name>
<name><surname>Imahorn</surname><given-names>E.</given-names></name>
<name><surname>Arias</surname><given-names>A.A.</given-names></name>
<name><surname>Vahidnezhad</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to beta-papillomaviruses</article-title><source>J. Exp. Med.</source><year>2018</year><volume>215</volume><fpage>2289</fpage><lpage>2310</lpage><pub-id pub-id-type="doi">10.1084/jem.20170308</pub-id><pub-id pub-id-type="pmid">30068544</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01439"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weissenborn</surname><given-names>S.J.</given-names></name>
<name><surname>Nindl</surname><given-names>I.</given-names></name>
<name><surname>Purdie</surname><given-names>K.</given-names></name>
<name><surname>Harwood</surname><given-names>C.</given-names></name>
<name><surname>Proby</surname><given-names>C.</given-names></name>
<name><surname>Breuer</surname><given-names>J.</given-names></name>
<name><surname>Majewski</surname><given-names>S.</given-names></name>
<name><surname>Pfister</surname><given-names>H.</given-names></name>
<name><surname>Wieland</surname><given-names>U.</given-names></name>
</person-group><article-title>Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers</article-title><source>J. Investig. Dermatol.</source><year>2005</year><volume>125</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23733.x</pub-id><pub-id pub-id-type="pmid">15982308</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01439"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arron</surname><given-names>S.T.</given-names></name>
<name><surname>Ruby</surname><given-names>J.G.</given-names></name>
<name><surname>Dybbro</surname><given-names>E.</given-names></name>
<name><surname>Ganem</surname><given-names>D.</given-names></name>
<name><surname>Derisi</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma</article-title><source>J. Investig. Dermatol.</source><year>2011</year><volume>131</volume><fpage>1745</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1038/jid.2011.91</pub-id><pub-id pub-id-type="pmid">21490616</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01439"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chockalingam</surname><given-names>R.</given-names></name>
<name><surname>Downing</surname><given-names>C.</given-names></name>
<name><surname>Tyring</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Cutaneous squamous cell carcinomas in organ transplant recipients</article-title><source>J. Clin. Med.</source><year>2015</year><volume>4</volume><fpage>1229</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.3390/jcm4061229</pub-id><pub-id pub-id-type="pmid">26239556</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01439"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bavinck</surname><given-names>J.N.B.</given-names></name>
<name><surname>Feltkamp</surname><given-names>M.C.W.</given-names></name>
<name><surname>Green</surname><given-names>A.C.</given-names></name>
<name><surname>Fiocco</surname><given-names>M.</given-names></name>
<name><surname>Euvrard</surname><given-names>S.</given-names></name>
<name><surname>Harwood</surname><given-names>C.A.</given-names></name>
<name><surname>Nasir</surname><given-names>S.</given-names></name>
<name><surname>Thomson</surname><given-names>J.</given-names></name>
<name><surname>Proby</surname><given-names>C.M.</given-names></name>
<name><surname>Naldi</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study</article-title><source>Am. J. Transplant.</source><year>2018</year><volume>18</volume><fpage>1220</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1111/ajt.14537</pub-id><pub-id pub-id-type="pmid">29024374</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01439"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasche</surname><given-names>D.</given-names></name>
<name><surname>Akg&#x000fc;l</surname><given-names>B.</given-names></name>
</person-group><article-title>Prevention and Treatment of HPV-Induced Skin Tumors</article-title><source>Cancers</source><year>2023</year><volume>15</volume><elocation-id>1709</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15061709</pub-id><pub-id pub-id-type="pmid">36980594</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01439"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasche</surname><given-names>D.</given-names></name>
<name><surname>Stephan</surname><given-names>S.</given-names></name>
<name><surname>Braspenning-Wesch</surname><given-names>I.</given-names></name>
<name><surname>Mikulec</surname><given-names>J.</given-names></name>
<name><surname>Niebler</surname><given-names>M.</given-names></name>
<name><surname>Gr&#x000f6;ne</surname><given-names>H.J.</given-names></name>
<name><surname>Flechtenmacher</surname><given-names>C.</given-names></name>
<name><surname>Akg&#x000fc;l</surname><given-names>B.</given-names></name>
<name><surname>R&#x000f6;sl</surname><given-names>F.</given-names></name>
<name><surname>Vinz&#x000f3;n</surname><given-names>S.E.</given-names></name>
</person-group><article-title>The interplay of UV and cutaneous papillomavirus infection in skin cancer development</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006723</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006723</pub-id><pub-id pub-id-type="pmid">29190285</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01439"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schaper</surname><given-names>I.D.</given-names></name>
<name><surname>Marcuzzi</surname><given-names>G.P.</given-names></name>
<name><surname>Weissenborn</surname><given-names>S.J.</given-names></name>
<name><surname>Kasper</surname><given-names>H.U.</given-names></name>
<name><surname>Dries</surname><given-names>V.</given-names></name>
<name><surname>Smyth</surname><given-names>N.</given-names></name>
<name><surname>Fuchs</surname><given-names>P.</given-names></name>
<name><surname>Pfister</surname><given-names>H.</given-names></name>
</person-group><article-title>Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>1394</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3263</pub-id><pub-id pub-id-type="pmid">15735026</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01439"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viarisio</surname><given-names>D.</given-names></name>
<name><surname>Mueller-Decker</surname><given-names>K.</given-names></name>
<name><surname>Kloz</surname><given-names>U.</given-names></name>
<name><surname>Aengeneyndt</surname><given-names>B.</given-names></name>
<name><surname>Kopp-Schneider</surname><given-names>A.</given-names></name>
<name><surname>Gr&#x000f6;ne</surname><given-names>H.J.</given-names></name>
<name><surname>Gheit</surname><given-names>T.</given-names></name>
<name><surname>Flechtenmacher</surname><given-names>C.</given-names></name>
<name><surname>Gissmann</surname><given-names>L.</given-names></name>
<name><surname>Tommasino</surname><given-names>M.</given-names></name>
</person-group><article-title>E6 and E7 from Beta Hpv38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002125</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002125</pub-id><pub-id pub-id-type="pmid">21779166</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01439"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hufbauer</surname><given-names>M.</given-names></name>
<name><surname>Lazic</surname><given-names>D.</given-names></name>
<name><surname>Akg&#x000fc;l</surname><given-names>B.</given-names></name>
<name><surname>Brandsma</surname><given-names>J.L.</given-names></name>
<name><surname>Pfister</surname><given-names>H.</given-names></name>
<name><surname>Weissenborn</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Enhanced human papillomavirus type 8 oncogene expression levels are crucial for skin tumorigenesis in transgenic mice</article-title><source>Virology</source><year>2010</year><volume>403</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.04.013</pub-id><pub-id pub-id-type="pmid">20451232</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01439"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viarisio</surname><given-names>D.</given-names></name>
<name><surname>M&#x000fc;ller-Decker</surname><given-names>K.</given-names></name>
<name><surname>Accardi</surname><given-names>R.</given-names></name>
<name><surname>Robitaille</surname><given-names>A.</given-names></name>
<name><surname>D&#x000fc;rst</surname><given-names>M.</given-names></name>
<name><surname>Beer</surname><given-names>K.</given-names></name>
<name><surname>Jansen</surname><given-names>L.</given-names></name>
<name><surname>Flechtenmacher</surname><given-names>C.</given-names></name>
<name><surname>Bozza</surname><given-names>M.</given-names></name>
<name><surname>Harbottle</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1006783</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006783</pub-id><pub-id pub-id-type="pmid">29324843</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01439"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>E.A.</given-names></name>
<name><surname>Kramer</surname><given-names>R.E.</given-names></name>
<name><surname>Tan</surname><given-names>M.J.</given-names></name>
<name><surname>Hayes</surname><given-names>S.D.</given-names></name>
<name><surname>Harper</surname><given-names>J.W.</given-names></name>
<name><surname>Howley</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>13174</fpage><lpage>131786</lpage><pub-id pub-id-type="doi">10.1128/JVI.02172-12</pub-id><pub-id pub-id-type="pmid">23015706</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01439"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>N.A.</given-names></name>
<name><surname>Robinson</surname><given-names>K.</given-names></name>
<name><surname>Howie</surname><given-names>H.L.</given-names></name>
<name><surname>Galloway</surname><given-names>D.A.</given-names></name>
</person-group><article-title>&#x003b2;-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004687</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004687</pub-id><pub-id pub-id-type="pmid">25803638</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01439"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akg&#x000fc;l</surname><given-names>B.</given-names></name>
<name><surname>Ghali</surname><given-names>L.</given-names></name>
<name><surname>Davies</surname><given-names>D.</given-names></name>
<name><surname>Pfister</surname><given-names>H.</given-names></name>
<name><surname>Leigh</surname><given-names>I.M.</given-names></name>
<name><surname>Storey</surname><given-names>A.</given-names></name>
</person-group><article-title>HPV8 early genes modulate differentiation and cell cycle of primary human adult keratinocytes</article-title><source>Exp. Dermatol.</source><year>2007</year><volume>16</volume><fpage>590</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2007.00569.x</pub-id><pub-id pub-id-type="pmid">17576239</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01439"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bandolin</surname><given-names>L.</given-names></name>
<name><surname>Borsetto</surname><given-names>D.</given-names></name>
<name><surname>Fussey</surname><given-names>J.</given-names></name>
<name><surname>Da Mosto</surname><given-names>M.C.</given-names></name>
<name><surname>Nicolai</surname><given-names>P.</given-names></name>
<name><surname>Menegaldo</surname><given-names>A.</given-names></name>
<name><surname>Calabrese</surname><given-names>L.</given-names></name>
<name><surname>Tommasino</surname><given-names>M.</given-names></name>
<name><surname>Boscolo-Rizzo</surname><given-names>P.</given-names></name>
</person-group><article-title>Beta human papillomaviruses infection and skin carcinogenesis</article-title><source>Rev. Med. Virol.</source><year>2020</year><volume>30</volume><fpage>e2104</fpage><pub-id pub-id-type="doi">10.1002/rmv.2104</pub-id><pub-id pub-id-type="pmid">32232924</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01439"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>E.A.</given-names></name>
<name><surname>Howley</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Proteomic approaches to the study of papillomavirus&#x02013;host interactions</article-title><source>Virology</source><year>2013</year><volume>435</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.09.046</pub-id><pub-id pub-id-type="pmid">23217616</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01439"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strickley</surname><given-names>J.D.</given-names></name>
<name><surname>Messerschmidt</surname><given-names>J.L.</given-names></name>
<name><surname>Awad</surname><given-names>M.E.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Hasegawa</surname><given-names>T.</given-names></name>
<name><surname>Ha</surname><given-names>D.T.</given-names></name>
<name><surname>Nabeta</surname><given-names>H.W.</given-names></name>
<name><surname>Bevins</surname><given-names>P.A.</given-names></name>
<name><surname>Ngo</surname><given-names>K.H.</given-names></name>
<name><surname>Asgari</surname><given-names>M.M.</given-names></name>
<etal/>
</person-group><article-title>Immunity to commensal papillomaviruses protects against skin cancer</article-title><source>Nature</source><year>2019</year><volume>575</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1719-9</pub-id><pub-id pub-id-type="pmid">31666702</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01439"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reschner</surname><given-names>A.</given-names></name>
<name><surname>Bontems</surname><given-names>S.</given-names></name>
<name><surname>Le Gac</surname><given-names>S.</given-names></name>
<name><surname>Lambermont</surname><given-names>J.</given-names></name>
<name><surname>Marcelis</surname><given-names>L.</given-names></name>
<name><surname>Defrancq</surname><given-names>E.</given-names></name>
<name><surname>Hubert</surname><given-names>P.</given-names></name>
<name><surname>Moucheron</surname><given-names>C.</given-names></name>
<name><surname>Mesmaeker</surname><given-names>K.-D.</given-names></name>
<name><surname>Raes</surname><given-names>M.</given-names></name>
</person-group><article-title>Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53</article-title><source>Gene Ther.</source><year>2013</year><volume>20</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/gt.2012.54</pub-id><pub-id pub-id-type="pmid">22809997</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01439"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Rao</surname><given-names>Z.</given-names></name>
</person-group><article-title>Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy</article-title><source>Cancer Biol. Ther.</source><year>2004</year><volume>3</volume><fpage>1129</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.4161/cbt.3.11.1215</pub-id><pub-id pub-id-type="pmid">15467442</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01439"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>E.M.</given-names></name>
<name><surname>Kornepati</surname><given-names>A.V.</given-names></name>
<name><surname>Goldstein</surname><given-names>M.</given-names></name>
<name><surname>Bogerd</surname><given-names>H.P.</given-names></name>
<name><surname>Poling</surname><given-names>B.C.</given-names></name>
<name><surname>Whisnant</surname><given-names>A.W.</given-names></name>
<name><surname>Kastan</surname><given-names>M.B.</given-names></name>
<name><surname>Cullen</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>11965</fpage><lpage>11972</lpage><pub-id pub-id-type="doi">10.1128/JVI.01879-14</pub-id><pub-id pub-id-type="pmid">25100830</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01439"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Cui</surname><given-names>Z.</given-names></name>
<name><surname>Jin</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells</article-title><source>Mol. Ther. Oncol.</source><year>2022</year><volume>24</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2021.12.011</pub-id><pub-id pub-id-type="pmid">35036522</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01439"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pogoda</surname><given-names>C.S.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.</given-names></name>
<name><surname>Garcea</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Immunizing against Anogenital Cancer: HPV Vaccines</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005587</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005587</pub-id><pub-id pub-id-type="pmid">27196109</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01439"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldstone</surname><given-names>S.E.</given-names></name>
<name><surname>Giuliano</surname><given-names>A.R.</given-names></name>
<name><surname>Palefsky</surname><given-names>J.M.</given-names></name>
<name><surname>Lazcano-Ponce</surname><given-names>E.</given-names></name>
<name><surname>Penny</surname><given-names>M.E.</given-names></name>
<name><surname>Cabello</surname><given-names>R.E.</given-names></name>
<name><surname>Moreira</surname><given-names>E.D.</given-names></name>
<name><surname>Baraldi</surname><given-names>E.</given-names></name>
<name><surname>Jessen</surname><given-names>H.</given-names></name>
<name><surname>Ferenczy</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, Immunogenicity, and Safety of a Quadrivalent HPV Vaccine in Men: Results of an Open-Label, Long-Term Extension of a Randomised, Placebo-Controlled, Phase 3 Trial</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00327-3</pub-id><pub-id pub-id-type="pmid">34780705</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01439"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bissett</surname><given-names>S.L.</given-names></name>
<name><surname>Draper</surname><given-names>E.</given-names></name>
<name><surname>Myers</surname><given-names>R.E.</given-names></name>
<name><surname>Godi</surname><given-names>A.</given-names></name>
<name><surname>Beddows</surname><given-names>S.</given-names></name>
</person-group><article-title>Cross-neutralizing antibodies elicited by the Cervarix(R) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.008</pub-id><pub-id pub-id-type="pmid">24440205</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01439"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hildesheim</surname><given-names>A.</given-names></name>
<name><surname>Herrero</surname><given-names>R.</given-names></name>
<name><surname>Wacholder</surname><given-names>S.</given-names></name>
<name><surname>Rodriguez</surname><given-names>A.C.</given-names></name>
<name><surname>Solomon</surname><given-names>D.</given-names></name>
<name><surname>Bratti</surname><given-names>M.C.</given-names></name>
<name><surname>Schiller</surname><given-names>J.T.</given-names></name>
<name><surname>Gonzalez</surname><given-names>P.</given-names></name>
<name><surname>Dubin</surname><given-names>G.</given-names></name>
<name><surname>Porras</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial</article-title><source>JAMA</source><year>2007</year><volume>298</volume><fpage>743</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1001/jama.298.7.743</pub-id><pub-id pub-id-type="pmid">17699008</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01439"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gay</surname><given-names>J.</given-names></name>
<name><surname>Johnson</surname><given-names>N.</given-names></name>
<name><surname>Kavuru</surname><given-names>V.</given-names></name>
<name><surname>Phillips</surname><given-names>M.</given-names></name>
</person-group><article-title>Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions</article-title><source>Skin Ther. Lett.</source><year>2021</year><volume>26</volume><fpage>6</fpage><lpage>8</lpage></element-citation></ref><ref id="B69-vaccines-12-01439"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00218;andru</surname><given-names>F.</given-names></name>
<name><surname>Radu</surname><given-names>A.M.</given-names></name>
<name><surname>Petca</surname><given-names>A.</given-names></name>
<name><surname>Dumitra&#x00219;cu</surname><given-names>M.C.</given-names></name>
<name><surname>Petca</surname><given-names>R.C.</given-names></name>
<name><surname>Roman</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases-A Comprehensive Review</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12030228</pub-id><pub-id pub-id-type="pmid">38543862</pub-id>
</element-citation></ref><ref id="B70-vaccines-12-01439"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>J.O.</given-names></name>
<name><surname>Son</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
<name><surname>Ko</surname><given-names>H.C.</given-names></name>
<name><surname>Kim</surname><given-names>B.S.</given-names></name>
<name><surname>Kim</surname><given-names>M.B.</given-names></name>
<name><surname>Shin</surname><given-names>K.</given-names></name>
</person-group><article-title>Nonavalent Human Papilloma Virus Vaccine for the Treatment of Multiple Recalcitrant Warts: An Open-Label Study</article-title><source>J. Am. Acad. Dermatol.</source><year>2022</year><volume>86</volume><fpage>940</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.03.074</pub-id><pub-id pub-id-type="pmid">33785384</pub-id>
</element-citation></ref><ref id="B71-vaccines-12-01439"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kost</surname><given-names>Y.</given-names></name>
<name><surname>Deutsch</surname><given-names>A.</given-names></name>
<name><surname>Zhu</surname><given-names>T.H.</given-names></name>
<name><surname>Hulur</surname><given-names>I.</given-names></name>
<name><surname>Blasiak</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Vaccination against Human Papillomavirus Is Not Associated with Resolution of Verruca Vulgaris in Immunocompetent 9- to 21-Year Olds</article-title><source>J. Am. Acad. Dermatol.</source><year>2022</year><volume>87</volume><fpage>250</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.08.016</pub-id><pub-id pub-id-type="pmid">34418514</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01439"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciccarese</surname><given-names>G.</given-names></name>
<name><surname>Herzum</surname><given-names>A.</given-names></name>
<name><surname>Serviddio</surname><given-names>G.</given-names></name>
<name><surname>Occella</surname><given-names>C.</given-names></name>
<name><surname>Parodi</surname><given-names>A.</given-names></name>
<name><surname>Drago</surname><given-names>F.</given-names></name>
</person-group><article-title>Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>7317</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12237317</pub-id><pub-id pub-id-type="pmid">38068369</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01439"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nofal</surname><given-names>E.</given-names></name>
<name><surname>Emam</surname><given-names>S.</given-names></name>
<name><surname>Aldesoky</surname><given-names>F.</given-names></name>
<name><surname>Ghonemy</surname><given-names>S.</given-names></name>
<name><surname>Adelshafy</surname><given-names>A.</given-names></name>
</person-group><article-title>Intralesional Bivalent Human Papilloma Virus Vaccine as a Treatment for Anogenital Warts versus Topical Podophyllin Resin 25%: A Pilot Study</article-title><source>Dermatol. Ther.</source><year>2022</year><volume>35</volume><fpage>e15384</fpage><pub-id pub-id-type="doi">10.1111/dth.15384</pub-id><pub-id pub-id-type="pmid">35170176</pub-id>
</element-citation></ref><ref id="B74-vaccines-12-01439"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fawzy</surname><given-names>M.</given-names></name>
<name><surname>Nofal</surname><given-names>E.</given-names></name>
<name><surname>Abdelkhalek</surname><given-names>N.</given-names></name>
<name><surname>Ehab</surname><given-names>R.</given-names></name>
</person-group><article-title>Intralesional Bivalent and Quadrivalent Human Papillomavirus Vaccines Didn&#x02019;t Significantly Enhance the Response of Multiple Anogenital Warts When Co-Administered with Intralesional Candida Antigen Immunotherapy. A Randomized Controlled Trial</article-title><source>Arch. Dermatol. Res.</source><year>2023</year><volume>315</volume><fpage>2813</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1007/s00403-023-02698-z</pub-id><pub-id pub-id-type="pmid">37573268</pub-id>
</element-citation></ref><ref id="B75-vaccines-12-01439"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Kim</surname><given-names>J.K.</given-names></name>
<name><surname>Kim</surname><given-names>D.H.</given-names></name>
<name><surname>Yoon</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18)</article-title><source>J. Am. Acad. Dermatol.</source><year>2011</year><volume>64</volume><fpage>e130</fpage><lpage>e132</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.12.032</pub-id><pub-id pub-id-type="pmid">21571164</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01439"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bossart</surname><given-names>S.</given-names></name>
<name><surname>Gabutti</surname><given-names>M.P.</given-names></name>
<name><surname>Seyed Jafari</surname><given-names>S.M.</given-names></name>
<name><surname>Hunger</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Nonavalent human papillomavirus vaccination as alternative treatment for genital warts</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e13771</fpage><pub-id pub-id-type="doi">10.1111/dth.13771</pub-id><pub-id pub-id-type="pmid">32500585</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01439"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreuter</surname><given-names>A.</given-names></name>
<name><surname>Wieland</surname><given-names>U.</given-names></name>
</person-group><article-title>Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients</article-title><source>J. Am. Acad. Dermatol.</source><year>2013</year><volume>68</volume><fpage>179</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2011.11.970</pub-id><pub-id pub-id-type="pmid">23244376</pub-id>
</element-citation></ref><ref id="B78-vaccines-12-01439"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilson</surname><given-names>R.</given-names></name>
<name><surname>Nugent</surname><given-names>D.</given-names></name>
<name><surname>Bennett</surname><given-names>K.</given-names></name>
<name><surname>Dor&#x000e9;</surname><given-names>C.J.</given-names></name>
<name><surname>Murray</surname><given-names>M.L.</given-names></name>
<name><surname>Meadows</surname><given-names>J.</given-names></name>
<name><surname>Haddow</surname><given-names>L.J.</given-names></name>
<name><surname>Lacey</surname><given-names>C.</given-names></name>
<name><surname>Sandmann</surname><given-names>F.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: The HIPvac factorial RCT</article-title><source>Health Technol. Assess.</source><year>2020</year><volume>24</volume><fpage>1</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.3310/hta24470</pub-id></element-citation></ref><ref id="B79-vaccines-12-01439"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nofal</surname><given-names>A.</given-names></name>
<name><surname>Nofal</surname><given-names>H.</given-names></name>
<name><surname>Alwirshiffani</surname><given-names>E.</given-names></name>
<name><surname>El Ghareeb</surname><given-names>M.I.</given-names></name>
</person-group><article-title>Treatment Response and Tolerability of Intralesional Quadrivalent versus Bivalent Human Papillomavirus Vaccine for Recalcitrant Warts: A Randomized Controlled Trial</article-title><source>J. Am. Acad. Dermatol.</source><year>2023</year><volume>89</volume><fpage>1051</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2023.06.042</pub-id><pub-id pub-id-type="pmid">37422014</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01439"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nyg&#x000e5;rd</surname><given-names>S.</given-names></name>
<name><surname>Nyg&#x000e5;rd</surname><given-names>M.</given-names></name>
<name><surname>Orumaa</surname><given-names>M.</given-names></name>
<name><surname>Hansen</surname><given-names>B.T.</given-names></name>
</person-group><article-title>Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>5469</fpage><lpage>5476</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.07.031</pub-id><pub-id pub-id-type="pmid">37516572</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01439"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nichols</surname><given-names>A.J.</given-names></name>
<name><surname>Allen</surname><given-names>A.H.</given-names></name>
<name><surname>Shareef</surname><given-names>S.</given-names></name>
<name><surname>Badiavas</surname><given-names>E.V.</given-names></name>
<name><surname>Kirsner</surname><given-names>R.S.</given-names></name>
<name><surname>Ioannides</surname><given-names>T.</given-names></name>
</person-group><article-title>Association of human papillomavirus vaccine with the development of keratinocyte carcinomas</article-title><source>JAMA Dermatol.</source><year>2017</year><volume>153</volume><fpage>571</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2016.5703</pub-id><pub-id pub-id-type="pmid">28196178</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01439"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nichols</surname><given-names>A.J.</given-names></name>
<name><surname>Gonzalez</surname><given-names>A.</given-names></name>
<name><surname>Clark</surname><given-names>E.S.</given-names></name>
<name><surname>Han</surname><given-names>W.N.</given-names></name>
<name><surname>Rosen</surname><given-names>A.C.</given-names></name>
<name><surname>Guzman</surname><given-names>W.</given-names></name>
<name><surname>Rabinovitz</surname><given-names>H.</given-names></name>
<name><surname>Badiavas</surname><given-names>E.V.</given-names></name>
<name><surname>Kirsner</surname><given-names>R.S.</given-names></name>
<name><surname>Ioannides</surname><given-names>T.</given-names></name>
</person-group><article-title>Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas</article-title><source>JAMA Dermatol.</source><year>2018</year><volume>154</volume><fpage>927</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2018.1748</pub-id><pub-id pub-id-type="pmid">29971321</pub-id>
</element-citation></ref><ref id="B83-vaccines-12-01439"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bossart</surname><given-names>S.</given-names></name>
<name><surname>Daneluzzi</surname><given-names>C.</given-names></name>
<name><surname>Moor</surname><given-names>M.B.</given-names></name>
<name><surname>Hirzel</surname><given-names>C.</given-names></name>
<name><surname>Heidemeyer</surname><given-names>K.</given-names></name>
<name><surname>Seyed Jafari</surname><given-names>S.M.</given-names></name>
<name><surname>Hunger</surname><given-names>R.E.</given-names></name>
<name><surname>Sidler</surname><given-names>D.</given-names></name>
</person-group><article-title>HPV Vaccination in Immunosuppressed Patients with Established Skin Warts and Non-Melanoma Skin Cancer: A Single-Institutional Cohort Study</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1490</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11091490</pub-id><pub-id pub-id-type="pmid">37766167</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01439"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wenande</surname><given-names>E.</given-names></name>
<name><surname>Bech-Thomsen</surname><given-names>N.</given-names></name>
<name><surname>Togsverd-Bo</surname><given-names>K.</given-names></name>
<name><surname>Haedersdal</surname><given-names>M.</given-names></name>
</person-group><article-title>Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series</article-title><source>Case Rep. Dermatol.</source><year>2021</year><volume>13</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1159/000518666</pub-id><pub-id pub-id-type="pmid">34720918</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01439"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreuter</surname><given-names>A.</given-names></name>
<name><surname>Waterboer</surname><given-names>T.</given-names></name>
<name><surname>Wieland</surname><given-names>U.</given-names></name>
</person-group><article-title>Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination</article-title><source>Arch. Dermatol.</source><year>2010</year><volume>146</volume><fpage>1196</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2010.290</pub-id><pub-id pub-id-type="pmid">20956677</pub-id>
</element-citation></ref><ref id="B86-vaccines-12-01439"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vinz&#x000f3;n</surname><given-names>S.E.</given-names></name>
<name><surname>Braspenning-Wesch</surname><given-names>I.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>M.</given-names></name>
<name><surname>Geissler</surname><given-names>E.K.</given-names></name>
<name><surname>Nindl</surname><given-names>I.</given-names></name>
<name><surname>Grone</surname><given-names>H.J.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>K.</given-names></name>
<name><surname>R&#x000f6;sl</surname><given-names>F.</given-names></name>
</person-group><article-title>Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: A preclinical study using a natural outbred animal model</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1003924</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003924</pub-id><pub-id pub-id-type="pmid">24586150</pub-id>
</element-citation></ref><ref id="B87-vaccines-12-01439"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gambhira</surname><given-names>R.</given-names></name>
<name><surname>Karanam</surname><given-names>B.</given-names></name>
<name><surname>Jagu</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>J.N.</given-names></name>
<name><surname>Buck</surname><given-names>C.B.</given-names></name>
<name><surname>Bossis</surname><given-names>I.</given-names></name>
<name><surname>Alphs</surname><given-names>H.</given-names></name>
<name><surname>Culp</surname><given-names>T.</given-names></name>
<name><surname>Christensen</surname><given-names>N.D.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.</given-names></name>
</person-group><article-title>S A protective and broadly cross-neutralizing epitope of human papillomavirus L2</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>13927</fpage><lpage>13931</lpage><pub-id pub-id-type="doi">10.1128/JVI.00936-07</pub-id><pub-id pub-id-type="pmid">17928339</pub-id>
</element-citation></ref><ref id="B88-vaccines-12-01439"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwak</surname><given-names>K.</given-names></name>
<name><surname>Jiang</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>J.W.</given-names></name>
<name><surname>Jagu</surname><given-names>S.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e97232</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0097232</pub-id><pub-id pub-id-type="pmid">24816794</pub-id>
</element-citation></ref><ref id="B89-vaccines-12-01439"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsakogiannis</surname><given-names>D.</given-names></name>
<name><surname>Nikolaidis</surname><given-names>M.</given-names></name>
<name><surname>Zagouri</surname><given-names>F.</given-names></name>
<name><surname>Zografos</surname><given-names>E.</given-names></name>
<name><surname>Kottaridi</surname><given-names>C.</given-names></name>
<name><surname>Kyriakopoulou</surname><given-names>Z.</given-names></name>
<name><surname>Tzioga</surname><given-names>L.</given-names></name>
<name><surname>Markoulatos</surname><given-names>P.</given-names></name>
<name><surname>Amoutzias</surname><given-names>G.D.</given-names></name>
<name><surname>Bletsa</surname><given-names>G.</given-names></name>
</person-group><article-title>Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas</article-title><source>Viruses</source><year>2022</year><volume>15</volume><elocation-id>141</elocation-id><pub-id pub-id-type="doi">10.3390/v15010141</pub-id><pub-id pub-id-type="pmid">36680181</pub-id>
</element-citation></ref><ref id="B90-vaccines-12-01439"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondo</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>Y.</given-names></name>
<name><surname>Ochi</surname><given-names>H.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Yoshikawa</surname><given-names>H.</given-names></name>
<name><surname>Kanda</surname><given-names>T.</given-names></name>
</person-group><article-title>Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region</article-title><source>Virology</source><year>2007</year><volume>358</volume><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.08.037</pub-id><pub-id pub-id-type="pmid">17010405</pub-id>
</element-citation></ref><ref id="B91-vaccines-12-01439"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.W.</given-names></name>
<name><surname>Jagu</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>W.H.</given-names></name>
<name><surname>Viscidi</surname><given-names>R.P.</given-names></name>
<name><surname>Macgregor-Das</surname><given-names>A.</given-names></name>
<name><surname>Fogel</surname><given-names>J.M.</given-names></name>
<name><surname>Kwak</surname><given-names>K.</given-names></name>
<name><surname>Daayana</surname><given-names>S.</given-names></name>
<name><surname>Kitchener</surname><given-names>H.</given-names></name>
<name><surname>Stern</surname><given-names>P.L.</given-names></name>
<etal/>
</person-group><article-title>Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>22</volume><fpage>806</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1128/CVI.00799-14</pub-id><pub-id pub-id-type="pmid">25972404</pub-id>
</element-citation></ref><ref id="B92-vaccines-12-01439"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jagu</surname><given-names>S.</given-names></name>
<name><surname>Karanam</surname><given-names>B.</given-names></name>
<name><surname>Gambhira</surname><given-names>R.</given-names></name>
<name><surname>Chivukula</surname><given-names>S.V.</given-names></name>
<name><surname>Chaganti</surname><given-names>R.J.</given-names></name>
<name><surname>Lowy</surname><given-names>D.R.</given-names></name>
<name><surname>Schiller</surname><given-names>J.T.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines</article-title><source>J. Natl. Cancer Inst.</source><year>2009</year><volume>101</volume><fpage>782</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp106</pub-id><pub-id pub-id-type="pmid">19470949</pub-id>
</element-citation></ref><ref id="B93-vaccines-12-01439"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalnin</surname><given-names>K.</given-names></name>
<name><surname>Tibbitts</surname><given-names>T.</given-names></name>
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Stegalkina</surname><given-names>S.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Costa</surname><given-names>V.</given-names></name>
<name><surname>Sabharwal</surname><given-names>R.</given-names></name>
<name><surname>Anderson</surname><given-names>S.F.</given-names></name>
<name><surname>Day</surname><given-names>P.M.</given-names></name>
<name><surname>Christensen</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3540</fpage><lpage>3547</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.032</pub-id><pub-id pub-id-type="pmid">24780250</pub-id>
</element-citation></ref><ref id="B94-vaccines-12-01439"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Qu</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcgammaRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>5531</fpage><lpage>5539</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.10.009</pub-id><pub-id pub-id-type="pmid">27729176</pub-id>
</element-citation></ref><ref id="B95-vaccines-12-01439"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spagnoli</surname><given-names>G.</given-names></name>
<name><surname>Bolchi</surname><given-names>A.</given-names></name>
<name><surname>Cavazzini</surname><given-names>D.</given-names></name>
<name><surname>Pouyanfard</surname><given-names>S.</given-names></name>
<name><surname>Muller</surname><given-names>M.</given-names></name>
<name><surname>Ottonello</surname><given-names>S.</given-names></name>
</person-group><article-title>Secretory production of designed multipeptides displayed on a thermostable bacterial thioredoxin scaffold in Pichia pastoris</article-title><source>Protein Expr. Purif.</source><year>2017</year><volume>129</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2016.04.012</pub-id><pub-id pub-id-type="pmid">27133916</pub-id>
</element-citation></ref><ref id="B96-vaccines-12-01439"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nieto</surname><given-names>K.</given-names></name>
<name><surname>Stahl-Hennig</surname><given-names>C.</given-names></name>
<name><surname>Leuchs</surname><given-names>B.</given-names></name>
<name><surname>Muller</surname><given-names>M.</given-names></name>
<name><surname>Gissmann</surname><given-names>L.</given-names></name>
<name><surname>Kleinschmidt</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques</article-title><source>Hum. Gene Ther.</source><year>2012</year><volume>23</volume><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1089/hum.2011.202</pub-id><pub-id pub-id-type="pmid">22401308</pub-id>
</element-citation></ref><ref id="B97-vaccines-12-01439"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>W.H.</given-names></name>
<name><surname>Alkutkar</surname><given-names>T.</given-names></name>
<name><surname>Karanam</surname><given-names>B.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.</given-names></name>
<name><surname>Ketner</surname><given-names>G.</given-names></name>
<name><surname>Ibeanu</surname><given-names>O.A.</given-names></name>
</person-group><article-title>Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: A candidate prophylactic hpv vaccine approach</article-title><source>Virol. J.</source><year>2015</year><volume>12</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0364-7</pub-id><pub-id pub-id-type="pmid">26362430</pub-id>
</element-citation></ref><ref id="B98-vaccines-12-01439"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vujadinovic</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Oosterhuis</surname><given-names>K.</given-names></name>
<name><surname>Uil</surname><given-names>T.G.</given-names></name>
<name><surname>Wunderlich</surname><given-names>K.</given-names></name>
<name><surname>Damman</surname><given-names>S.</given-names></name>
<name><surname>Boedhoe</surname><given-names>S.</given-names></name>
<name><surname>Verwilligen</surname><given-names>A.</given-names></name>
<name><surname>Knibbe</surname><given-names>J.</given-names></name>
<name><surname>Serroyen</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>4462</fpage><lpage>4470</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.024</pub-id><pub-id pub-id-type="pmid">29914845</pub-id>
</element-citation></ref><ref id="B99-vaccines-12-01439"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tumban</surname><given-names>E.</given-names></name>
<name><surname>Peabody</surname><given-names>J.</given-names></name>
<name><surname>Peabody</surname><given-names>D.S.</given-names></name>
<name><surname>Chackerian</surname><given-names>B.</given-names></name>
</person-group><article-title>A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e23310</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0023310</pub-id><pub-id pub-id-type="pmid">21858066</pub-id>
</element-citation></ref><ref id="B100-vaccines-12-01439"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>S.W.</given-names></name>
<name><surname>Lee</surname><given-names>T.Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Lee</surname><given-names>I.H.</given-names></name>
<name><surname>Sung</surname><given-names>M.H.</given-names></name>
<name><surname>Park</surname><given-names>J.S.</given-names></name>
<name><surname>Poo</surname><given-names>H.</given-names></name>
</person-group><article-title>Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>3286</fpage><lpage>3294</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.009</pub-id><pub-id pub-id-type="pmid">22426329</pub-id>
</element-citation></ref><ref id="B101-vaccines-12-01439"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huber</surname><given-names>B.</given-names></name>
<name><surname>Schellenbacher</surname><given-names>C.</given-names></name>
<name><surname>Shafti-Keramat</surname><given-names>S.</given-names></name>
<name><surname>Jindra</surname><given-names>C.</given-names></name>
<name><surname>Christensen</surname><given-names>N.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0169533</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169533</pub-id><pub-id pub-id-type="pmid">28056100</pub-id>
</element-citation></ref><ref id="B102-vaccines-12-01439"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schellenbacher</surname><given-names>C.</given-names></name>
<name><surname>Kwak</surname><given-names>K.</given-names></name>
<name><surname>Fink</surname><given-names>D.</given-names></name>
<name><surname>Shafti-Keramat</surname><given-names>S.</given-names></name>
<name><surname>Huber</surname><given-names>B.</given-names></name>
<name><surname>Jindra</surname><given-names>C.</given-names></name>
<name><surname>Faust</surname><given-names>H.</given-names></name>
<name><surname>Dillner</surname><given-names>J.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.S.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses</article-title><source>J. Investig. Dermatol.</source><year>2013</year><volume>133</volume><fpage>2706</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.253</pub-id><pub-id pub-id-type="pmid">23752042</pub-id>
</element-citation></ref><ref id="B103-vaccines-12-01439"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schellenbacher</surname><given-names>C.</given-names></name>
<name><surname>Roden</surname><given-names>R.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>10085</fpage><lpage>10095</lpage><pub-id pub-id-type="doi">10.1128/JVI.01088-09</pub-id><pub-id pub-id-type="pmid">19640991</pub-id>
</element-citation></ref><ref id="B104-vaccines-12-01439"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huber</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>J.W.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.S.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>1044</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10051044</pub-id><pub-id pub-id-type="pmid">33802456</pub-id>
</element-citation></ref><ref id="B105-vaccines-12-01439"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmels</surname><given-names>M.</given-names></name>
<name><surname>Mariz</surname><given-names>F.C.</given-names></name>
<name><surname>Braspenning-Wesch</surname><given-names>I.</given-names></name>
<name><surname>Stephan</surname><given-names>S.</given-names></name>
<name><surname>Huber</surname><given-names>B.</given-names></name>
<name><surname>Schmidt</surname><given-names>G.</given-names></name>
<name><surname>Cao</surname><given-names>R.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>M.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
<name><surname>R&#x000f6;sl</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1010790</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1010790</pub-id><pub-id pub-id-type="pmid">36263027</pub-id>
</element-citation></ref><ref id="B106-vaccines-12-01439"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mariz</surname><given-names>F.C.</given-names></name>
<name><surname>Balz</surname><given-names>K.</given-names></name>
<name><surname>Dittrich</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Bolchi</surname><given-names>A.</given-names></name>
<name><surname>Ottonello</surname><given-names>S.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>M.</given-names></name>
</person-group><article-title>A broadly protective vaccine against cutaneous human papillomaviruses</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00539-0</pub-id><pub-id pub-id-type="pmid">36216845</pub-id>
</element-citation></ref><ref id="B107-vaccines-12-01439"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olczak</surname><given-names>P.</given-names></name>
<name><surname>Matsui</surname><given-names>K.</given-names></name>
<name><surname>Wong</surname><given-names>M.</given-names></name>
<name><surname>Alvarez</surname><given-names>J.</given-names></name>
<name><surname>Lambert</surname><given-names>P.</given-names></name>
<name><surname>Christensen</surname><given-names>N.D.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Huber</surname><given-names>B.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>J.W.</given-names></name>
<etal/>
</person-group><article-title>RG2-VLP: A vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0056622</fpage><pub-id pub-id-type="doi">10.1128/jvi.00566-22</pub-id><pub-id pub-id-type="pmid">35703545</pub-id>
</element-citation></ref><ref id="B108-vaccines-12-01439"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mo</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>C.</given-names></name>
</person-group><article-title>Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>909223</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.909223</pub-id><pub-id pub-id-type="pmid">35860379</pub-id>
</element-citation></ref><ref id="B109-vaccines-12-01439"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chabeda</surname><given-names>A.</given-names></name>
<name><surname>Yanez</surname><given-names>R.J.R.</given-names></name>
<name><surname>Lamprecht</surname><given-names>R.</given-names></name>
<name><surname>Meyers</surname><given-names>A.E.</given-names></name>
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
<name><surname>Hitzeroth</surname><given-names>I.I.</given-names></name>
</person-group><article-title>Therapeutic Vaccines for High-Risk HPV-Associated Diseases</article-title><source>Papillomavirus Res.</source><year>2018</year><volume>5</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.pvr.2017.12.006</pub-id><pub-id pub-id-type="pmid">29277575</pub-id>
</element-citation></ref><ref id="B110-vaccines-12-01439"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>J.A.</given-names></name>
<name><surname>Haberstroh</surname><given-names>F.S.</given-names></name>
<name><surname>White</surname><given-names>E.A.</given-names></name>
<name><surname>Livingston</surname><given-names>D.M.</given-names></name>
<name><surname>DeCaprio</surname><given-names>J.A.</given-names></name>
<name><surname>Howley</surname><given-names>P.M.</given-names></name>
</person-group><article-title>SMCX and Components of the TIP60 Complex Contribute to E2 Regulation of the HPV E6/E7 Promoter</article-title><source>Virology</source><year>2014</year><volume>468&#x02013;470</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.08.022</pub-id></element-citation></ref><ref id="B111-vaccines-12-01439"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hufbauer</surname><given-names>M.</given-names></name>
<name><surname>Rattay</surname><given-names>S.</given-names></name>
<name><surname>Hagen</surname><given-names>C.</given-names></name>
<name><surname>Quaas</surname><given-names>A.</given-names></name>
<name><surname>Pfister</surname><given-names>H.</given-names></name>
<name><surname>Hartmann</surname><given-names>G.</given-names></name>
<name><surname>Coch</surname><given-names>C.</given-names></name>
<name><surname>Akg&#x000fc;l</surname><given-names>B.</given-names></name>
</person-group><article-title>Poly(I:C) Treatment Prevents Skin Tumor Formation in the Preclinical HPV8 Transgenic Mouse Model</article-title><source>J. Investig. Dermatol.</source><year>2023</year><volume>143</volume><fpage>1197</fpage><lpage>1207.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2022.12.007</pub-id><pub-id pub-id-type="pmid">36584911</pub-id>
</element-citation></ref><ref id="B112-vaccines-12-01439"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santin</surname><given-names>A.D.</given-names></name>
<name><surname>Bellone</surname><given-names>S.</given-names></name>
<name><surname>Palmieri</surname><given-names>M.</given-names></name>
<name><surname>Zanolini</surname><given-names>A.</given-names></name>
<name><surname>Ravaggi</surname><given-names>A.</given-names></name>
<name><surname>Siegel</surname><given-names>E.R.</given-names></name>
<name><surname>Roman</surname><given-names>J.J.</given-names></name>
<name><surname>Pecorelli</surname><given-names>S.</given-names></name>
<name><surname>Cannon</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: A Phase I Escalating Dose Trial</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>1968</fpage><lpage>1979</lpage><pub-id pub-id-type="doi">10.1128/JVI.02343-07</pub-id><pub-id pub-id-type="pmid">18057249</pub-id>
</element-citation></ref><ref id="B113-vaccines-12-01439"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basu</surname><given-names>P.</given-names></name>
<name><surname>Mehta</surname><given-names>A.</given-names></name>
<name><surname>Jain</surname><given-names>M.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Nagarkar</surname><given-names>R.V.</given-names></name>
<name><surname>John</surname><given-names>S.</given-names></name>
<name><surname>Petit</surname><given-names>R.</given-names></name>
</person-group><article-title>A Randomized Phase 2 Study of ADXS11-001 Listeria MonocytogenesListeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer</article-title><source>Int. J. Gynecol. Cancer</source><year>2018</year><volume>28</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1097/IGC.0000000000001235</pub-id><pub-id pub-id-type="pmid">29538258</pub-id>
</element-citation></ref><ref id="B114-vaccines-12-01439"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Massarelli</surname><given-names>E.</given-names></name>
<name><surname>William</surname><given-names>W.</given-names></name>
<name><surname>Johnson</surname><given-names>F.</given-names></name>
<name><surname>Kies</surname><given-names>M.</given-names></name>
<name><surname>Ferrarotto</surname><given-names>R.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>Lee</surname><given-names>J.J.</given-names></name>
<name><surname>Tran</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.U.</given-names></name>
<etal/>
</person-group><article-title>Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.4051</pub-id><pub-id pub-id-type="pmid">30267032</pub-id>
</element-citation></ref><ref id="B115-vaccines-12-01439"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Poelgeest</surname><given-names>M.I.</given-names></name>
<name><surname>Welters</surname><given-names>M.J.</given-names></name>
<name><surname>van Esch</surname><given-names>E.M.</given-names></name>
<name><surname>Stynenbosch</surname><given-names>L.F.</given-names></name>
<name><surname>Kerpershoek</surname><given-names>G.</given-names></name>
<name><surname>van Persijn van Meerten</surname><given-names>E.L.</given-names></name>
<name><surname>van den Hende</surname><given-names>M.</given-names></name>
<name><surname>L&#x000f6;wik</surname><given-names>M.J.</given-names></name>
<name><surname>Berends-van der Meer</surname><given-names>D.M.</given-names></name>
<name><surname>Fathers</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial</article-title><source>J. Transl. Med.</source><year>2013</year><volume>11</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-11-88</pub-id><pub-id pub-id-type="pmid">23557172</pub-id>
</element-citation></ref><ref id="B116-vaccines-12-01439"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Mao</surname><given-names>L.</given-names></name>
<name><surname>Ou</surname><given-names>R.</given-names></name>
<name><surname>Ding</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Jia</surname><given-names>Z.</given-names></name>
<name><surname>Tian</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Heat Shock Protein 110 Improves the Antitumor Effects of the Cytotoxic T Lymphocyte Epitope E7(49-57) in Mice</article-title><source>Cancer Biol. Ther.</source><year>2010</year><volume>9</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.2.10391</pub-id><pub-id pub-id-type="pmid">19901562</pub-id>
</element-citation></ref><ref id="B117-vaccines-12-01439"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arribillaga</surname><given-names>L.</given-names></name>
<name><surname>Echeverria</surname><given-names>I.</given-names></name>
<name><surname>Belsue</surname><given-names>V.</given-names></name>
<name><surname>Gomez</surname><given-names>T.</given-names></name>
<name><surname>Lozano</surname><given-names>T.</given-names></name>
<name><surname>Casares</surname><given-names>N.</given-names></name>
<name><surname>Villanueva</surname><given-names>L.</given-names></name>
<name><surname>Domingos-Pereira</surname><given-names>S.</given-names></name>
<name><surname>Romero</surname><given-names>P.J.</given-names></name>
<name><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Bivalent Therapeutic Vaccine Against HPV16/18 Genotypes Consisting of a Fusion Protein Between the Extra Domain A From Human Fibronectin and HPV16/18 E7 Viral Antigens</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>e000704</fpage><pub-id pub-id-type="doi">10.1136/jitc-2020-000704</pub-id><pub-id pub-id-type="pmid">32581060</pub-id>
</element-citation></ref><ref id="B118-vaccines-12-01439"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weissenborn</surname><given-names>S.J.</given-names></name>
<name><surname>De Koning</surname><given-names>M.N.</given-names></name>
<name><surname>Wieland</surname><given-names>U.</given-names></name>
<name><surname>Quint</surname><given-names>W.G.</given-names></name>
<name><surname>Pfister</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Intrafamilial transmission and family-specific spectra of cutaneous betapapillomaviruses</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>811</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1128/JVI.01338-08</pub-id><pub-id pub-id-type="pmid">18987132</pub-id>
</element-citation></ref><ref id="B119-vaccines-12-01439"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>J.Y.</given-names></name>
<name><surname>Chen</surname><given-names>A.C.</given-names></name>
<name><surname>Keleher</surname><given-names>A.</given-names></name>
<name><surname>McMillan</surname><given-names>N.A.</given-names></name>
<name><surname>Antonsson</surname><given-names>A.</given-names></name>
</person-group><article-title>Shared and persistent asymptomatic cutaneous human papillomavirus infections in healthy skin</article-title><source>J. Med. Virol.</source><year>2009</year><volume>81</volume><fpage>1444</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1002/jmv.21529</pub-id><pub-id pub-id-type="pmid">19551818</pub-id>
</element-citation></ref><ref id="B120-vaccines-12-01439"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van der Burg</surname><given-names>S.</given-names></name>
<name><surname>Kwappenberg</surname><given-names>K.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>T.</given-names></name>
<name><surname>Brandt</surname><given-names>R.</given-names></name>
<name><surname>Melief</surname><given-names>C.</given-names></name>
<name><surname>Hickling</surname><given-names>J.</given-names></name>
<name><surname>Offringa</surname><given-names>R.</given-names></name>
</person-group><article-title>Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>3652</fpage><lpage>3660</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00086-X</pub-id><pub-id pub-id-type="pmid">11395199</pub-id>
</element-citation></ref><ref id="B121-vaccines-12-01439"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Jong</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>T.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Kwappenberg</surname><given-names>K.</given-names></name>
<name><surname>Chisholm</surname><given-names>S.</given-names></name>
<name><surname>Whittle</surname><given-names>N.</given-names></name>
<name><surname>Dobson</surname><given-names>J.</given-names></name>
<name><surname>Jack</surname><given-names>L.</given-names></name>
<name><surname>Roberts</surname><given-names>J.S.C.</given-names></name>
<name><surname>Offringa</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3456</fpage><lpage>3464</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00350-X</pub-id><pub-id pub-id-type="pmid">12297390</pub-id>
</element-citation></ref><ref id="B122-vaccines-12-01439"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daayana</surname><given-names>S.</given-names></name>
<name><surname>Elkord</surname><given-names>E.</given-names></name>
<name><surname>Winters</surname><given-names>U.</given-names></name>
<name><surname>Pawlita</surname><given-names>M.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.S.</given-names></name>
<name><surname>Stern</surname><given-names>P.L.</given-names></name>
<name><surname>Kitchener</surname><given-names>H.C.</given-names></name>
</person-group><article-title>Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>1129</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605611</pub-id><pub-id pub-id-type="pmid">20234368</pub-id>
</element-citation></ref><ref id="B123-vaccines-12-01439"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>H.</given-names></name>
<name><surname>Davies</surname><given-names>M.</given-names></name>
<name><surname>Holding</surname><given-names>F.</given-names></name>
<name><surname>Fallon</surname><given-names>R.</given-names></name>
<name><surname>Mann</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>T.</given-names></name>
<name><surname>Roberts</surname><given-names>J.S.C.</given-names></name>
</person-group><article-title>Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00146-7</pub-id><pub-id pub-id-type="pmid">10078606</pub-id>
</element-citation></ref><ref id="B124-vaccines-12-01439"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lacey</surname><given-names>C.J.N.</given-names></name>
<name><surname>Thompson</surname><given-names>H.S.G.</given-names></name>
<name><surname>Monteiro</surname><given-names>E.F.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>T.</given-names></name>
<name><surname>Davies</surname><given-names>M.L.</given-names></name>
<name><surname>Holding</surname><given-names>F.P.</given-names></name>
<name><surname>Fallon</surname><given-names>R.E.</given-names></name>
<name><surname>Roberts</surname><given-names>J.S.C.</given-names></name>
</person-group><article-title>Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>179</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1086/314616</pub-id><pub-id pub-id-type="pmid">9952367</pub-id>
</element-citation></ref><ref id="B125-vaccines-12-01439"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vandepapeli&#x000e8;re</surname><given-names>P.</given-names></name>
<name><surname>Barrasso</surname><given-names>R.</given-names></name>
<name><surname>Meijer</surname><given-names>C.J.L.M.</given-names></name>
<name><surname>Walboomers</surname><given-names>J.M.M.</given-names></name>
<name><surname>Wettendorff</surname><given-names>M.</given-names></name>
<name><surname>Stanberry</surname><given-names>L.R.</given-names></name>
<name><surname>Lacey</surname><given-names>C.J.N.</given-names></name>
</person-group><article-title>Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>192</volume><fpage>2099</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1086/498164</pub-id><pub-id pub-id-type="pmid">16288373</pub-id>
</element-citation></ref><ref id="B126-vaccines-12-01439"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Gambhira</surname><given-names>R.</given-names></name>
<name><surname>Karanam</surname><given-names>B.</given-names></name>
<name><surname>Monie</surname><given-names>A.</given-names></name>
<name><surname>Hung</surname><given-names>C.-F.</given-names></name>
<name><surname>Roden</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>T.-C.</given-names></name>
</person-group><article-title>Generation and characterization of a preventive and therapeutic HPV DNA vaccine</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.019</pub-id><pub-id pub-id-type="pmid">18096279</pub-id>
</element-citation></ref><ref id="B127-vaccines-12-01439"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>R.T.</given-names></name>
<name><surname>Wang</surname><given-names>J.W.</given-names></name>
<name><surname>Peng</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>T.C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Cannella</surname><given-names>F.</given-names></name>
<name><surname>Chang</surname><given-names>Y.N.</given-names></name>
<name><surname>Viscidi</surname><given-names>R.</given-names></name>
<name><surname>Best</surname><given-names>S.R.A.</given-names></name>
<name><surname>Hung</surname><given-names>C.-F.</given-names></name>
<etal/>
</person-group><article-title>Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e00699-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.00699-17</pub-id><pub-id pub-id-type="pmid">28515303</pub-id>
</element-citation></ref><ref id="B128-vaccines-12-01439"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bloom</surname><given-names>K.</given-names></name>
<name><surname>van den Berg</surname><given-names>F.</given-names></name>
<name><surname>Arbuthnot</surname><given-names>P.</given-names></name>
</person-group><article-title>Self-amplifying RNA vaccines for infectious diseases</article-title><source>Gene Ther.</source><year>2021</year><volume>28</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/s41434-020-00204-y</pub-id><pub-id pub-id-type="pmid">33093657</pub-id>
</element-citation></ref><ref id="B129-vaccines-12-01439"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brito</surname><given-names>L.A.</given-names></name>
<name><surname>Kommareddy</surname><given-names>S.</given-names></name>
<name><surname>Maione</surname><given-names>D.</given-names></name>
<name><surname>Uematsu</surname><given-names>Y.</given-names></name>
<name><surname>Giovani</surname><given-names>C.</given-names></name>
<name><surname>Scorza</surname><given-names>F.B.</given-names></name>
<name><surname>Otten</surname><given-names>G.R.</given-names></name>
<name><surname>Yu</surname><given-names>D.</given-names></name>
<name><surname>Mandl</surname><given-names>C.W.</given-names></name>
<name><surname>Mason</surname><given-names>P.W.</given-names></name>
<etal/>
</person-group><article-title>Self-Amplifying mRNA Vaccines</article-title><source>Adv. Genet.</source><year>2015</year><volume>89</volume><fpage>179</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/bs.adgen.2014.10.005</pub-id><pub-id pub-id-type="pmid">25620012</pub-id>
</element-citation></ref><ref id="B130-vaccines-12-01439"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bottomley</surname><given-names>M.J.</given-names></name>
<name><surname>Thomson</surname><given-names>J.</given-names></name>
<name><surname>Harwood</surname><given-names>C.</given-names></name>
<name><surname>Leigh</surname><given-names>I.</given-names></name>
</person-group><article-title>The Role of the Immune System in Cutaneous Squamous Cell Carcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>2009</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20082009</pub-id><pub-id pub-id-type="pmid">31022866</pub-id>
</element-citation></ref><ref id="B131-vaccines-12-01439"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pardoll</surname><given-names>D.M.</given-names></name>
</person-group><article-title>The Blockade of Immune Checkpoints in Cancer Immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id>
</element-citation></ref><ref id="B132-vaccines-12-01439"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naumann</surname><given-names>R.W.</given-names></name>
<name><surname>Leath</surname><given-names>C.A.</given-names><suffix>3rd</suffix></name>
</person-group><article-title>Advances in Immunotherapy for Cervical Cancer</article-title><source>Curr. Opin. Oncol.</source><year>2020</year><volume>32</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1097/CCO.0000000000000663</pub-id><pub-id pub-id-type="pmid">32740092</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01439-f001"><label>Figure 1</label><caption><p>Interventions available and under development for mucosal and cutaneous HPV infections. Prophylactic vaccination with licensed L1-VLPs and screening by cytology and HPV tests are established methods to prevent or monitor mucosal HPV infection. Although not approved, L1-VLPs may also be used to treat pre-existing infection. Prophylactic vaccination targeting beta HPVs and therapeutic vaccination against mucosal and cutaneous HPVs are still under development. Antiviral compounds against HPV proteins are presently not on hand and the development is still in an experimental stage.</p></caption><graphic xlink:href="vaccines-12-01439-g001" position="float"/></fig></floats-group></article>